<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000966" GROUP_ID="SCHIZ" ID="708299101610344264" MERGED_FROM="" MODIFIED="2012-01-18 21:14:51 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;Exported from Review Manager 4.2.3&lt;br&gt;Short title (no longer in use): Newer atypicals vs clozapine for schizophrenia&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2008-10-29 16:35:54 +0000" NOTES_MODIFIED_BY="[Empty name]" REVIEW_NO="0030" REVMAN_SUB_VERSION="5.0.16" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="9.0">
<COVER_SHEET MODIFIED="2012-01-18 21:14:51 +0100" MODIFIED_BY="Claire Irving">
<TITLE>Newer atypical antipsychotic medication versus clozapine for schizophrenia</TITLE>
<CONTACT MODIFIED="2012-01-18 21:14:51 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="13240" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arja</FIRST_NAME><LAST_NAME>Tuunainen</LAST_NAME><EMAIL_1>arja.tuunainen@helsinki.fi</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Helsinki</ORGANISATION><ADDRESS_1>Lapinlahdentie</ADDRESS_1><ADDRESS_2>P.O.Box 320</ADDRESS_2><CITY>Hus</CITY><ZIP>FIN 00029</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 9 471 81263</PHONE_1><FAX_1>+358 9 471 81316</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2012-01-18 21:14:51 +0100" MODIFIED_BY="Claire Irving"><PERSON ID="13240" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Arja</FIRST_NAME><LAST_NAME>Tuunainen</LAST_NAME><EMAIL_1>arja.tuunainen@helsinki.fi</EMAIL_1><ADDRESS><DEPARTMENT>Department of Psychiatry</DEPARTMENT><ORGANISATION>University of Helsinki</ORGANISATION><ADDRESS_1>Lapinlahdentie</ADDRESS_1><ADDRESS_2>P.O.Box 320</ADDRESS_2><CITY>Hus</CITY><ZIP>FIN 00029</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 9 471 81263</PHONE_1><FAX_1>+358 9 471 81316</FAX_1></ADDRESS></PERSON><PERSON ID="16295" ROLE="AUTHOR"><PREFIX>Prof</PREFIX><FIRST_NAME>Kristian</FIRST_NAME><LAST_NAME>Wahlbeck</LAST_NAME><POSITION>Professor of Psychiatry</POSITION><EMAIL_1>kristian.wahlbeck@thl.fi</EMAIL_1><EMAIL_2>kristian.wahlbeck@helsinki.fi</EMAIL_2><ADDRESS><DEPARTMENT>Department of Mental Health and Substance Abuse Services</DEPARTMENT><ORGANISATION>THL National Institute for Health and Welfare</ORGANISATION><ADDRESS_2>PO Box 220</ADDRESS_2><CITY>Helsinki</CITY><ZIP>FIN-00531</ZIP><COUNTRY CODE="FI">Finland</COUNTRY><PHONE_1>+358 20 610 7300</PHONE_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-10-29 15:25:17 +0000" MODIFIED_BY="Bethany York" NOTES="&lt;p&gt;Minor update: 2/20/00&lt;/p&gt;" NOTES_MODIFIED="2008-10-29 15:25:17 +0000" NOTES_MODIFIED_BY="Bethany York">
<UP_TO_DATE>
<DATE DAY="20" MONTH="2" YEAR="2000"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="20" MONTH="2" YEAR="2000"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="29" MONTH="2" YEAR="2000"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1998"/>
<REVIEW_PUBLISHED ISSUE="4" YEAR="1998"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2000"/>
</DATES>
<WHATS_NEW MODIFIED="2012-01-18 21:14:51 +0100" MODIFIED_BY="Claire Irving" NOTES="&lt;p&gt;The updated review includes eight studies (22 papers), whereas the previous version included four studies (18 papers).&lt;br&gt;The text has been checked throughout and updated.&lt;br&gt;&lt;br&gt;Odds ratio (OR) statistic has been changed to relative risk (RR) statistic.&lt;br&gt;&lt;br&gt;New variables (psychosis symptoms rating scale, deterioration in mental state or relapse, depression, social functioning, treatment satisfaction, seizures) have been added to the variable list.&lt;br&gt;&lt;br&gt;&lt;/p&gt;"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 21:14:51 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="18" MONTH="1" YEAR="2012"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2012-01-18 21:14:51 +0100" MODIFIED_BY="Claire Irving"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2012-01-18 21:14:51 +0100" MODIFIED_BY="Claire Irving"><DATE DAY="11" MONTH="11" YEAR="2009"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-11-11 11:41:41 +0100" MODIFIED_BY="Claire Irving">
<DATE DAY="29" MONTH="10" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="20" MONTH="2" YEAR="2000"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Helsinki University Central Hospital (HUCH)</NAME>
<COUNTRY CODE="FI">Finland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>NHS Centre for Reviews and Dissemination, University of York</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of California San Diego</NAME>
<COUNTRY CODE="US">USA</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>National Research and Development Centre for Welfare and Health (STAKES)</NAME>
<COUNTRY CODE="FI">Finland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>Finska Läkaresällskapet (Finnish Medical Society)</NAME>
<COUNTRY CODE="FI">Finland</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-10-29 15:54:39 +0000" MODIFIED_BY="[Empty name]">
<SUMMARY MODIFIED="2008-10-29 15:50:58 +0000" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2008-10-29 15:50:58 +0000" MODIFIED_BY="[Empty name]">Newer atypical antipsychotic medication versus clozapine for schizophrenia</TITLE>
<SUMMARY_BODY>
<P>Synopsis pending.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Clozapine is an atypical antipsychotic drug, which is claimed to have superior efficacy and to cause fewer movement disorders. However, clozapine carries a significant risk of serious blood disorders. Newer atypical antipsychotics are safer alternatives that might share the benefits of clozapine. It is thus of interest to compare the effectiveness of newer atypical antipsychotics with the effectiveness of clozapine.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>To evaluate the clinical effects of newer atypical antipsychotic drugs in comparison to clozapine for schizophrenia.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>Publications in all languages were searched from the following databases: Biological Abstracts/BIOSIS (1980-1999), The Cochrane Schizophrenia Group's Register of Trials (1998), The Cochrane Library CENTRAL Register (Issue 4, 1999), EMBASE (1980-1998), MEDLINE (1966-1999), LILACS/CD-ROM (1998), and PsycLIT/PsycINFO (1974-1999). Trials were also sought from recent conference proceedings and reference lists of included papers. Authors of recent trials and the manufacturers of clozapine, iloperidone, olanzapine, quetiapine, remoxipride, risperidone, sertindole, ziprasidone and zotepine were contacted.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>All randomised controlled trials comparing clozapine with newer atypical antipsychotic drugs were included by independent assessment by two reviewers.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Data were extracted independently by two reviewers. Relative risks (RR) and 95% confidence intervals (CI) of homogenous dichotomous data were calculated. A random effects model was used for heterogeneous dichotomous data. Where possible the number needed to treat (NNT) statistic with 95%CI were also calculated. Weighted or standardised means were calculated for continuous data. Due to the small number of included studies, sensitivity analyses or funnel plot statistics were not undertaken for this version of the review.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>The current review includes eight studies (22 papers), of which three studies are 4-6 weeks in duration and only one study is of more than 12 weeks' duration.<BR/> <BR/>Newer atypical drugs seemed to be broadly similar to clozapine using a clinical global index or trialists' definitions of improvement, but this result was obtained from a relatively small number of studies. Due to the small number of studies and patients, wide confidence intervals were seen when their effectiveness as measured by symptom rating scales was compared. Social functioning was better in patients on newer atypical medication (risperidone) than in those on clozapine, but this finding is based on a single underpowered trial and has to be interpreted with caution.</P>
<P>Clozapine and newer atypical drugs showed their adverse effect profile to be dissimilar: while clozapine produced more fatigue, hypersalivation, nausea, and orthostatic dizziness, new atypical drugs, with the exception of olanzapine, produced more extrapyramidal symptoms.</P>
<P>The impact of these drugs and their effects on patients' day-to-day quality of life, service use, hospital admission, and pharmacoeconomics was not measured.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>The equal effectiveness and tolerability of new atypical drugs in comparison with clozapine is not yet demonstrated. Lack of statistical power to determine the comparative efficacy and effectiveness of newer atypical drugs makes it difficult to judge whether newer drugs are more effective, less effective or equivalent. Trials of sufficient power, with longer duration, measuring clinically important outcomes, are needed to assess the true comparative clinical effectiveness, tolerability and cost effectiveness of newer drugs in relation to clozapine.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-10-29 15:53:40 +0000" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-10-29 15:30:22 +0000" MODIFIED_BY="[Empty name]">
<P>Typical antipsychotic drugs are widely used as the first line treatment for people with schizophrenia, in the acute as well as in chronic forms of the illness (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>, <LINK REF="REF-Silverstone-1995" TYPE="REFERENCE">Silverstone 1995</LINK>). However, adverse effects, such as movement disorders and sedation, are problematic and can result in non-compliance with medication. Positive symptoms, such as delusions, hallucinations and thought disorder are more florid in acute phases of the illness than negative symptoms, such as poverty of speech, lack of motivation, apathy and inability to express emotions (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>). Negative symptoms, however, are more disabling and may not respond as well to typical antipsychotic drugs (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>).</P>
<P>'Atypical' is a term widely used to describe some antipsychotics with specific characteristics such as minimal risk of acute and chronic movement disorders and less sedation (<LINK REF="REF-Kerwin-1994" TYPE="REFERENCE">Kerwin 1994</LINK>). The atypical antipsychotic drugs are also thought to be more effective than conventional drugs in treatment of negative symptoms in schizophrenia (<LINK REF="REF-Silverstone-1995" TYPE="REFERENCE">Silverstone 1995</LINK>), although this has not yet been adequately established (<LINK REF="REF-Kane-1996a" TYPE="REFERENCE">Kane 1996a</LINK>). At present, new antipsychotics are routinely investigated for their possible effect on negative symptoms (<LINK REF="REF-EMEA-1998" TYPE="REFERENCE">EMEA 1998</LINK>).</P>
<P>Clozapine was one of the first atypical drugs to be introduced (<LINK REF="REF-Silverstone-1995" TYPE="REFERENCE">Silverstone 1995</LINK>, <LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>). It is known to have a reduced tendency to cause stiffness and repetitive movements, the so-called extrapyramidal side effects (EPS) (<LINK REF="REF-Claghorn-1987" TYPE="REFERENCE">Claghorn 1987</LINK>). However, it is associated with a reversible (but potentially fatal) blood disorder: a loss of granulocytic white blood cells called agranulocytosis. For this reason, in many countries its use is restricted to those patients who have not improved with conventional antipsychotics. Frequent (usually weekly) blood tests have to be undertaken for patients being treated with clozapine. Recently, potentially fatal cardiac complications were also reported to be associated with clozapine use (<LINK REF="REF-Kilian-1999" TYPE="REFERENCE">Kilian 1999</LINK>). A number of other, newer atypical drugs such as risperidone, olanzapine, sertindole, quetiapine, zotepine, ziprasidone, remoxipride and iloperidone have been introduced for the treatment of schizophrenia in recent years (<LINK REF="REF-Kerwin-1996" TYPE="REFERENCE">Kerwin 1996</LINK>). These newer atypical drugs are considered to be safer than clozapine, although there have been a few case reports on olanzapine-induced neutropenia (<LINK REF="REF-Benedetti-1999" TYPE="REFERENCE">Benedetti 1999</LINK>, <LINK REF="REF-Steinwachs-1999" TYPE="REFERENCE">Steinwachs 1999</LINK>) and agranulocytosis (<LINK REF="REF-Naumann-1999" TYPE="REFERENCE">Naumann 1999</LINK>). Remoxipride, which has been available since 1984, has been withdrawn on a worldwide basis, due to case reports of aplastic anaemia, but it remains available for named patients and for compassionate use (<LINK REF="REF-De-Prins-1997" TYPE="REFERENCE">De Prins 1997</LINK>). Due to the concern regarding sertindole's cardiotoxicity, in some countries the drug has been withdrawn or marketing delayed, until more studies on its safety profile are available.</P>
<P>The pharmacological profile of clozapine shows a high affinity for certain areas in the brain (D1, D4 and 5HT2 receptors) and a low affinity for other areas (D2 receptors). The receptor affinity for risperidone is different from clozapine (high affinity for D2 and 5HT2 receptors), and the pharmacological profiles of other drugs are either clozapine- or risperidone-like (<LINK REF="REF-Kerwin-1996" TYPE="REFERENCE">Kerwin 1996</LINK>). There is some suggestion that the different adverse effect profiles of atypical antipsychotic medications make them more acceptable as drugs - hence increasing compliance (<LINK REF="REF-Casey-1997" TYPE="REFERENCE">Casey 1997</LINK>). These purported benefits and their clinical effects have not yet been fully evaluated in systematic reviews.</P>
<P>According to recent treatment guidelines, both conventional and newer atypical antipsychotic drugs may be reasonable choices in the treatment of schizophrenia (<LINK REF="REF-APA-1997" TYPE="REFERENCE">APA 1997</LINK>). Clozapine is known to be more effective than conventional antipsychotics (<LINK REF="REF-Wahlbeck-1999" TYPE="REFERENCE">Wahlbeck 1999</LINK>, <LINK REF="REF-Kane-1988" TYPE="REFERENCE">Kane 1988</LINK>). However, atypical drugs, other than clozapine, may also be effective in treatment resistant patients (<LINK REF="REF-Schooler-1997" TYPE="REFERENCE">Schooler 1997</LINK>, <LINK REF="REF-Kane-1996b" TYPE="REFERENCE">Kane 1996b</LINK>), and may therefore be a viable alternative to clozapine. Atypical antipsychotics are more expensive than conventional drugs (<LINK REF="REF-Meltzer-1996" TYPE="REFERENCE">Meltzer 1996</LINK>), but are hypothesised to reduce a person's need for inpatient services and associated costs (<LINK REF="REF-Buckley-1997" TYPE="REFERENCE">Buckley 1997</LINK>, <LINK REF="REF-Glazer-1997" TYPE="REFERENCE">Glazer 1997</LINK>). Estimates on the cost effectiveness of different atypical antipsychotics are required and should balance the increased cost of drugs and unwanted adverse effects with improvement in outcome and resulting savings from reduced service use (<LINK REF="REF-Robert-1997" TYPE="REFERENCE">Robert 1997</LINK>). Such cost-effectiveness studies should rely upon realistic and believable estimates of their clinical effectiveness.</P>
</BACKGROUND>
<OBJECTIVES>
<P>The primary objective of the review was to compare the clinical effects of clozapine with newer atypical antipsychotic drugs in the short term (up to 12 weeks), medium term (up to 26 weeks) and long term (more than 26 weeks) treatment of schizophrenia.</P>
<P>It was also intended to clarify if:<BR/>1. those with their illness described as 'treatment resistant' differ in their treatment response from those whose illnesses were not grouped as such; and <BR/>2. those with their first episode of schizophrenia differ in their response to medication in comparison with those who have had several episodes of the illness.</P>
</OBJECTIVES>
<METHODS MODIFIED="2008-10-29 15:53:40 +0000" MODIFIED_BY="[Empty name]">
<SELECTION_CRITERIA MODIFIED="2008-10-29 15:52:18 +0000" MODIFIED_BY="[Empty name]">
<CRIT_STUDIES>
<P>All relevant randomised controlled trials. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>People with schizophrenia, and other types of schizophrenia-like psychoses (schizophreniform and schizoaffective disorders) were included. There is no evidence that the schizophrenia-like psychoses are caused by fundamentally different disease processes or require different treatment approaches (<LINK REF="REF-Carpenter-1994" TYPE="REFERENCE">Carpenter 1994</LINK>).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>1. New atypical antipsychotic drugs, that is, any other antipsychotic drug such as iloperidone, olanzapine (trade marks Lanzac, Zyprex, Zyprexa), quetiapine (Seroquel), remoxipride (Remidon, Roxiam), risperidone (Belivon, Risperdal, Risperin, Rispolin), sertindole (Serdolect, Serlect), ziprasidone (Zeldox), or zotepine (Lodopin, Majorpin, Nipolept, Setous, Zopite): any dose.</P>
<P>2. Clozapine (trade marks Clozaril, Froidir, Leponex): any dose.</P>
<P>All the new atypical antipsychotic drugs are serotonin-dopamine antagonists (SDAs). Older atypical drugs, without significant action on the serotonin receptor, such as sulpiride and amisulpride, were excluded from this review.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-10-29 15:52:18 +0000" MODIFIED_BY="[Empty name]">
<P>All outcomes were grouped by time - short term (up to 12 weeks), medium term (up to 26 weeks) and long term (more than 26 weeks). As schizophrenia is a long-term disorder, short treatment studies are not clinically relevant, and a decision was made to exclude studies lasting less than two weeks. In crossover studies, only the first treatment phase prior to crossover (first arm) was included.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-10-29 15:51:56 +0000" MODIFIED_BY="[Empty name]">
<P>Principal outcomes of interest were:<BR/>1. clinically significant improvement in mental state (as defined in individual studies) with particular reference to the positive and negative symptoms of schizophrenia (one should be aware of the fact that cut-off points are arbitrary, and that the use of different criteria, i.e. various cut-off points, in different studies may have a major impact on the meta-analysis results);<BR/>2. adverse effects, particularly extrapyramidal side effects (movement disorders) and other possible adverse effects (for instance, blood reactions and epileptic seizures);<BR/>3. acceptability of treatment both as assessed directly by questioning trial participants and indirectly by the numbers dropping out from studies; and<BR/>4. deterioration in mental state or relapse as defined in individual studies.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-10-29 15:52:09 +0000" MODIFIED_BY="[Empty name]">
<P>Information was also sought regarding other outcomes including (objective or subjective measures):<BR/>1. overall clinical improvement;<BR/>2. quality of life;<BR/>3. wocial functioning;<BR/>4. cognitive functioning;<BR/>5. hospital status, either discharge or readmission as defined in individual trials;<BR/>6. employment status;<BR/>7. family burden;<BR/>8. death, both as suicide and other causes; and<BR/>9. cost effectiveness.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-10-29 15:53:40 +0000" MODIFIED_BY="[Empty name]">
<P>The trials were located from sources as listed below.</P>
<ELECTRONIC_SEARCHES MODIFIED="2008-10-29 15:53:00 +0000" MODIFIED_BY="[Empty name]">
<P>1. Searches of commercial databases:</P>
<P>1.1. Biological Abstracts/BIOSIS (1980 - December 19, 1999) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and ((clozapin* or clozaril or leponex) and (olanzapin* or lanzac or zyprex* or quetiapin* or seroquel or risperidon* or belivon or risperdal or risperin or rispolin or sertindol* or serdolect or serlect or ziprasidon* or zotepin* or lodopin or nipolept or zopite or setous or majorpin or remoxiprid* or roxiam or remidon or iloperidon*))].</P>
<P>1.2. Cochrane Schizophrenia Group's Register of Trials (December 3, 1998) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and ((clozapin* or clozaril or leponex or #42=28) and (olanzapin* or lanzac or zyprex* or #42=427 or quetiapin* or seroquel or #42=428 or<BR/>risperidon* or belivon or risperdal or risperin or rispolin or #42=142 or sertindol* or serdolect or serlect or #42=426 or ziprasidon* or #42=429 or zotepin* or lodopin or nipolept or zopite or setous or majorpin or #42=138 or remoxiprid* or roxiam or remidon or #42=141 or iloperidon*))].</P>
<P>1.3. The Cochrane Library CENTRAL Register (Issue 4, 1999) was searched using the phrase:</P>
<P>((clozapin* or clozaril or leponex) and (olanzapin* or lanzac or zyprex* or quetiapin* or seroquel or risperidon* or belivon or risperdal or risperin or rispolin or sertindol* or serdolect or serlect or ziprasidon* or zotepin* or lodopin or nipolept or zopite or setous or majorpin or remoxiprid* or roxiam or remidon or iloperidon*)).</P>
<P>1.4. EMBASE (1980 - November 20, 1998) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and ((clozapin* or clozaril or leponex or explode CLOZAPINE / all) and ((olanzapin* or lanzac or zyprex* or explode OLANZAPINE / all) or<BR/>(quetiapin* or seroquel or explode QUETIAPINE / all) or (remoxiprid* or remidon or roxiam or explode REMOXIPRIDE / all) or (risperidon* or belivon or risperdal or risperin or rispolin or explode RISPERIDONE / all) or (sertindol* or serdolect or serlect or explode SERTINDOLE / all) or (ziprasidon* or explode ZIPRASIDONE / all) or (zotepin* or lodopin or majorpin or nipolept or setous or zopite or explode ZOTEPINE / all) or iloperidon*))].</P>
<P>1.5. MEDLINE (1966 - December 12, 1999) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and ((clozapin* or clozaril or leponex or explode CLOZAPINE / all) and (olanzapin* or lanzac or zyprex*) or (quetiapin* or seroquel) or (risperidon* or belivon or risperdal or risperin or rispolin or explode RISPERIDONE / all) or (sertindol* or serdolect or serlect) or ziprasidon* or (zotepin* or lodopin or nipolept or zopite or setous or majorpin) or (remoxiprid* or roxiam or remidon) or iloperidon*)].</P>
<P>1.6. LILACS/CD-ROM 30th edition (January 1998) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and ((clozapin* or clozaril or leponex or explode CLOZAPINE / all) and (olanzapin* or lanzac or zyprex*) or (quetiapin* or seroquel) or (risperidon* or belivon or risperdal or risperin or rispolin or explode RISPERIDONE / all) or (sertindol* or serdolect or serlect) or ziprasidon* or (zotepin* or lodopin or nipolept or zopite or setous or majorpin) or (remoxiprid* or roxiam or remidon) or iloperidon*)].</P>
<P>1.7. PsycLIT/PsycINFO (1974 - December 19, 1999) was searched using the Cochrane Schizophrenia Group's phrase for randomised controlled trials and schizophrenia (see Group search strategy) combined with the phrase:</P>
<P>[and ((clozapin* or clozaril or leponex) and (olanzapin* or lanzac or zyprex* or quetiapin* or seroquel or remoxiprid* or remidon or roxiam or risperidon* or belivon or risperdal or risperin or rispolin or sertindol* or serdolect or serlect or zotepin* or lodopine or majorpin or nipolept or setous or zopite or ziprasidon*))].</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-10-29 15:53:40 +0000" MODIFIED_BY="[Empty name]">
<P>2. Reference lists: All references of articles selected were searched for further relevant trials.</P>
<P>3. Conferences: Studies were sought from recent conference proceedings (if available).</P>
<P>4. Pharmaceutical companies: Those companies performing trials with clozapine, iloperidone, olanzapine, quetiapine, remoxipride, risperidone, sertindole, ziprasidone or zotepine were contacted directly to obtain data on unpublished trials.</P>
<P>5. Personal contact: The first author of each study was contacted for information regarding unpublished trials.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION>
<P>Study selection<BR/>All study citations identified by the searches were independently inspected by two reviewers (AT and SG or KW) to assess their relevance to this review. Full reports of the studies of agreed relevance were obtained. When disagreement occurred, the full article was acquired for further inspection. If there was disagreement with the inspection of the report, this was resolved by discussion and further information was sought from the authors when needed. These trials were added to the list of those awaiting assessment until further information was acquired and review criteria could be evaluated.</P>
<P>Quality assessment<BR/>Two reviewers (AT and SG or KW), also independently, evaluated the quality of allocation concealment of all included trials. A rating was given for each trial based on the three quality categories as described in the Cochrane Collaboration Handbook (<LINK REF="REF-Mulrow-1997" TYPE="REFERENCE">Mulrow 1997</LINK>). When disputes arose, resolution was attempted by discussion. If this was not possible and further information was needed to clarify into which category to allocate the trial, data was not entered and the trial was allocated to the list of those awaiting assessment. Only trials in Category A or B were included in the review. Double-blind studies with no further information on randomisation process were included in Category B.</P>
<P>Addressing publication bias<BR/>Data from all identified and selected trials were entered into a funnel graph (trial effect versus trial size) in an attempt to investigate the likelihood of overt publication bias. Where appropriate funnel plot asymmetry (suggesting potential publication bias) was investigated by visual inspection and formal statistical tests (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>).<BR/> <BR/>Data extraction<BR/>Data from selected trials were independently extracted by two reviewers, and when disputes arose, resolution was attempted by discussion. When this was not possible and further information was necessary to resolve the dilemma, data were not entered until the authors were contacted and additional information was obtained. </P>
<P>Data synthesis<BR/>Outcomes were assessed using continuous (for example, changes on a behaviour scale), categorical (for example, one of three categories on a behaviour scale, such as 'little change', 'moderate change' or 'much change') or dichotomous measures (for example, either 'no important changes' or 'important changes' in a person's behaviour). </P>
<P>1. Dichotomous data<BR/>If possible, efforts were made to convert outcome measures to dichotomous data. This was done by identifying cut-off points on rating scales and dividing subjects accordingly into 'clinically improved' or 'not clinically improved'. If the authors of a study had used a designated cut-off point for determining clinical effectiveness this was used by the reviewers when appropriate. (These cut-offs, however, are quite arbitrary, and it is problematic to compare for instance studies using criteria of 20% reduction and of 50% reduction in scores, respectively). Based on the Cochrane Schizophrenia Group's guideline, we changed the odds ratio (OR) statistic of the previous version of this review to the relative risk (RR) statistic with the 95% confidence interval (CI). A random effects model was used for heterogeneous dichotomous data. As a measure of effectiveness, the number needed to treat (NNT) or the number needed to harm (NNH) statistic was also calculated together with its confidence interval. Where patients were lost to follow-up at the end of the study, it was assumed that they had had a poor outcome and once they were randomised they were included in the analysis (intention to treat analysis). This assumption was not considered in the number of deaths. Suicide was also treated as a relapse. If patients dropped out after randomisation due to non-compliance, lack of efficacy, relapse, or for unknown reason, those cases were also included in the deterioration in mental state or relapse data. These rules were agreed upon by the reviewers before the data extraction process.</P>
<P>2. Continuous data<BR/>A wide range of rating scales is available to measure outcomes in mental health trials. These instruments vary in quality and many are not validated, or even ad hoc. It is generally accepted that measuring instruments should have the properties of reliability (the repeatability of the test result) and validity (the extent to which a test measures that which it is supposed to measure). Before publication of an instrument, most scientific journals insist that reliability and validity be demonstrated to the satisfaction of the referees. It was therefore decided, as a minimum standard, not to include any data from an instrument in this review unless the instrument and its properties had been published in a peer-reviewed journal. In addition, the following minimum standards for instruments were set: the instrument should either be: (a) a self-report, or (b) completed by an independent rater or relative (not the therapist); and the instrument should be a global assessment of an area of functioning. Continuous data were reported as presented in the original studies, without making any assumptions about those lost to follow-up. Whenever possible, the opportunity was taken to make direct comparisons between trials that used the same measurement instrument to quantify specific outcomes. Where continuous data were presented from different scales rating the same effect, data were combined into a common outcome variable if appropriate, and the general direction of effect was inspected. For these combined continuous data, a standardised mean difference statistic was used.</P>
<P>Data on outcomes in neuroleptic trials are often not normally distributed. To avoid the pitfall of applying parametric tests to non-parametric data the following standards were applied to data derived from continuous measures of end point 'state'. The criteria were used before inclusion:<BR/>1. standard deviations (SDs) and means were reported in the paper or were obtainable from the authors; and<BR/>2. SD, when multiplied by two was less than the mean (as otherwise the mean was unlikely to be an appropriate measure of the centre of the distribution) (<LINK REF="REF-Altman-1996" TYPE="REFERENCE">Altman 1996</LINK>). </P>
<P>Data that did not meet the first or second standard were not entered into a meta-analysis, but into RevMan software separately. </P>
<P>For continuous mean change data (endpoint minus baseline) the situation is even more problematic. In the absence of individual patient data it is impossible to know if change data is skewed. The RevMan meta-analyses of continuous data are based on the assumption that the data are, at least to a reasonable degree, normally distributed. It is quite feasible that change data is skewed but, after consulting the ALLSTAT 1988 electronic statistics mailing list (http://www.stats.gla.ac.uk/allstat/index.html), it was entered into RevMan in order to summarise the available information. In doing this it is assumed that either data were not skewed or that the analyses within RevMan could cope with the unknown degree of skewness. Without individual trial data it is not possible to formally check this assumption.</P>
<P>Graphs <BR/>In all cases the data were entered into RevMan in such a way that the area to the left of the 'line of no effect' indicated a favourable outcome for newer atypical drugs.</P>
<P>Sensitivity analysis<BR/>The reviewers planned to undertake six sensitivity analyses. These were to investigate whether:<BR/>1. trials using rigorous diagnostic criteria systematically differed in their results from trials using more pragmatic entry criteria;<BR/>2. the decision to assume that those who did not complete the studies had a poor outcome resulted in a substantially different result from when only data from those who completed the trial were analysed;<BR/>3. trials sponsored by the manufacturer differed from non-sponsored trials; <BR/>4. trials on any single new atypical antipsychotic drug differed in effectiveness from clozapine; <BR/>5. those who were considered as 'treatment resistant' differed in their response compared to those without this designation; and <BR/>6. those with their first episode of schizophrenia differed in their response to medication compared to those with several episodes of the illness.</P>
<P>Test for heterogeneity<BR/>In addition to inspecting the graphical presentations, the reviewers checked whether the differences among the results of trials were greater than would be expected by chance alone using tests of heterogeneity. A significance level less than 0.10 was interpreted as heterogeneity. Where heterogeneity was detected, potential sources were investigated (such as differences in dosage, patient group and length of follow-up).</P>
<P>Pooled data <BR/>Our approach to pool together studies on all newer atypical drugs and compare the data as a group with clozapine is problematic, because newer atypical drugs are not identical to each other: they have different profiles of action and various adverse effects. One of our sensitivity analyses was to study whether single new atypical drugs differ in effectiveness from clozapine.</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION>
<P>Excluded studies<BR/>Most of the reported studies comparing clozapine with other atypical antipsychotic drugs are non-randomised, open trials, and have been excluded from this review due to failure to meet inclusion criteria. </P>
<P>One study (<LINK REF="STD-Meyer_x002d_Lindenberg1997" TYPE="STUDY">Meyer-Lindenberg1997</LINK>) was originally conducted as a randomised controlled trial but was analysed and reported as a non-randomised study. High attrition rates in one treatment group resulted in baseline differences between the two groups of patients who completed the study. Rather than present an 'intention to treat' analysis, the authors chose to match subgroups of patients from each treatment group and reported differences in performance on cognitive tests (one of the chosen outcome measures) - excluding several of the randomised patients that completed the study. Allocation and analysis according to baseline randomisation was therefore broken. Useful data from this study may be included in a further version of the review, pending further data from the authors. </P>
<P>Two studies (<LINK REF="STD-Su-1997" TYPE="STUDY">Su 1997</LINK>, <LINK REF="STD-Daniel-1996" TYPE="STUDY">Daniel 1996</LINK>) have been set on a waiting list due to the crossover design of their studies. Further clarification of the results of the first treatment prior to crossover is sought from the authors (this phase of the study, prior to crossover, being equivalent to a conventional randomised trial. One study (<LINK REF="STD-Estrella-1996" TYPE="STUDY">Estrella 1996</LINK>) is still waiting for clarification about allocation design, and two ongoing studies (<LINK REF="STD-Lewis-2000" TYPE="STUDY">Lewis 2000</LINK>, <LINK REF="STD-Meltzer-2000" TYPE="STUDY">Meltzer 2000</LINK>) will be included in later versions of this review. </P>
<P>Included studies<BR/>Eight trials (22 papers) were identified for inclusion in this review. One trial (<LINK REF="STD-Remox_x002f_Risp_x002f_Zote-1996" TYPE="STUDY">Remox/Risp/Zote 1996</LINK>) randomly assigned patients to one of six different medication groups - one of which was clozapine and four of which included other atypical drugs (risperidone 4mg, risperidone 8mg, remoxipride and zotepine). For this review, we pooled the data of all atypical drugs of the study and compared them with the clozapine data. Pooling was performed by combining the weighted data according to sample size in each atypical condition. </P>
<P>One study is to be published soon (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>). Two others (<LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK>, <LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>) have been reported only as conference abstracts and await full publication in a peer-reviewed journal. One study has been reported only in marketing material by the manufacturer of clozapine (<LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK>).</P>
<P>Diagnostic heterogeneity<BR/>All of the included studies reported stringent criteria for the diagnosis of schizophrenia.</P>
<P>Definitions<BR/>Definitions of improvement in condition varied across studies. Studies used the following criteria: percentage of respondents with 20% decrease in BPRS (<LINK REF="STD-Risperidone-1999" TYPE="STUDY">Risperidone 1999</LINK>, <LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK>) or in PANSS total score (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>, <LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>). Additional criteria were used in <LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK> and <LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK>. The criteria were not specified in the rest of the studies. </P>
<P>Study length<BR/>Only one study (<LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>) was 18 weeks in duration ('medium term' category). All the other trials were in the 'short term' category: two trials lasted for four weeks (<LINK REF="STD-Remox_x002f_Risp_x002f_Zote-1996" TYPE="STUDY">Remox/Risp/Zote 1996</LINK>, <LINK REF="STD-Remoxipride-1994" TYPE="STUDY">Remoxipride 1994</LINK>), one six weeks (<LINK REF="STD-Risperidone-1999" TYPE="STUDY">Risperidone 1999</LINK>), two eight weeks (<LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>), one 10 weeks (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>) and one 12 weeks (<LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK>). There were no long term studies (extending more than 26 weeks). </P>
<P>Design<BR/>The included studies are all randomised and double-blind except for <LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>, which is a single-blind study (a blind rater). The blindness of one study (<LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK>) is as yet unknown.</P>
<P>Sample size<BR/>Sample size ranged from 20 patients (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>) to 273 patients (<LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK>), with a mean size 107. The total number of patients from the eight studies that might provide data for pooling is 795.</P>
<P>Participants<BR/>All eight studies included people with a diagnosis of schizophrenia, and two trials (<LINK REF="STD-Remox_x002f_Risp_x002f_Zote-1996" TYPE="STUDY">Remox/Risp/Zote 1996</LINK>, <LINK REF="STD-Remoxipride-1994" TYPE="STUDY">Remoxipride 1994</LINK>) specified the patients to suffer from the paranoid type. Five studies (<LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK>, <LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>, <LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>, <LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK>) included only the treatment-resistant patients, and one trial included the patients with partial response to neuroleptics (<LINK REF="STD-Risperidone-1999" TYPE="STUDY">Risperidone 1999</LINK>). The criteria for treatment-resistance were not identical in the included studies. All trials used either International Classification of Diseases (ICD-9) or Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria DSM-III-R or DSM-IV. Participants were more likely to be male than female (66% versus 34%, respectively), had a mean age of 37 years, and an average duration of illness of about seven years. One study included patients with acute schizophrenia paranoid type with no previous medication (<LINK REF="STD-Remoxipride-1994" TYPE="STUDY">Remoxipride 1994</LINK>), and in two trials the premedication was not strictly defined or the information was not available (<LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK>, <LINK REF="STD-Remox_x002f_Risp_x002f_Zote-1996" TYPE="STUDY">Remox/Risp/Zote 1996</LINK>).</P>
<P>Settings<BR/>Two studies (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>) reported the setting to be hospital in the beginning of the trial, while the rest of the studies did not state whether patients were inpatients or outpatients. Three studies were multicentre (<LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>, <LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK>): in <LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK> the people in the first trial were recruited from France and Canada, in the second, from Germany and Switzerland, and in the last, from 14 countries.</P>
<P>Interventions<BR/>1. Newer atypical antipsychotic drugs: drugs and doses used varied and were fixed or flexible. The mean daily dose of remoxipride was 375mg (<LINK REF="STD-Remoxipride-1994" TYPE="STUDY">Remoxipride 1994</LINK>). In the study with pooled atypical drugs (<LINK REF="STD-Remox_x002f_Risp_x002f_Zote-1996" TYPE="STUDY">Remox/Risp/Zote 1996</LINK>), the doses of risperidone were 4mg/day and 8mg/day, 400 mg/day for remoxipride and 200 mg/day for zotepine. In the other studies with risperidone, the mean doses were 7.8mg/day (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>), 5.9mg/day (<LINK REF="STD-Risperidone-1999" TYPE="STUDY">Risperidone 1999</LINK>), 8.3mg/day (<LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK>), and 6.4mg/day (<LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>), respectively. Olanzapine was delivered 15-25mg/day (<LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>). </P>
<P>2. Clozapine: the doses were either fixed or flexible, and varied from 150-900mg/day.<BR/>
<LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK> did not report the doses of either drug.</P>
<P>Outcomes<BR/>The treatment effects were evaluated both by dichotomous and continuous symptom scales. Acceptability of treatment was measured both by patient dissatisfaction and dropping out from the study (for whatever reason). Deterioration in several aspects of living and well-being were assessed: quality of life, social functioning, cognitive functioning, inability to work, family burden, pharmacoeconomics. Adverse effects in detail were evaluated by dichotomous scales. If the study did not declare the number of patients suffering from extrapyramidal symptoms, the number of patients in need of medications for extrapyramidal symptoms was used for the analysis. Abbreviations of the tests are explained in the footnotes of the Characteristics of Studies table.</P>
<P>The following rating scales provided usable data for this review:</P>
<P>Adverse effect scales<BR/>Simpson-Angus Scale (SAS) (<LINK REF="REF-Simpson-1970" TYPE="REFERENCE">Simpson 1970</LINK>) is a standardised physical examination which measures drug-induced parkinsonism. The scale comprises a 10-item rating scale, each item rated on a five-point scale from zero (complete absence of condition) to four (presence of condition in extreme). The total score is the sum of ratings on the 10 items divided by ten. </P>
<P>Cognitive scales<BR/>Syndrome Short Test (Syndrom Kurztest, SKT) (<LINK REF="REF-Erzigkeit-1986" TYPE="REFERENCE">Erzigkeit 1986</LINK>) is a German rating scale that evaluates cognitive changes. Higher scores indicate poorer performance.</P>
<P>Short Test for General Intelligence (Kurztest für Allgemeine Intelligence, KAI) (<LINK REF="REF-Lehrl-1980" TYPE="REFERENCE">Lehrl 1980</LINK>) is a German rating scale that evaluates general intelligence. Higher values indicate better performance.</P>
<P>Global assessment scales<BR/>Clinical Global Impressions (CGI) (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) is a rating instrument that assesses severity of illness. It consists of three global scales (items), of which two items, 'Severity of illness' and 'Global improvement', are rated on a seven-point scale; while the third, 'Efficacy index', requires a rating of the interaction of a therapeutic effectiveness and adverse reactions. Lower scores indicate decreased severity and/or greater recovery.<BR/> <BR/>Global Assessment of Functioning (GAF) (<LINK REF="REF-APA-1994" TYPE="REFERENCE">APA 1994</LINK>) is a clinician-rated assessment of overall functioning, which considers psychological, social, and occupational functioning on a scale 0-100. Lower scores indicate poorer functioning. <BR/> <BR/>Patient Global Impression (PGI) (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>) is a self-report scale assessing global improvement. The scale is derived from the clinician-rated CGI (<LINK REF="REF-Guy-1976" TYPE="REFERENCE">Guy 1976</LINK>). Improvement is rated on a seven-point scale from one (very much better) to seven (very much worse).</P>
<P>Mental state scales<BR/>Brief Psychiatric Rating Scale (BPRS) (<LINK REF="REF-Overall-1962" TYPE="REFERENCE">Overall 1962</LINK>) is a brief rating scale which is used to assess the severity of a range of psychiatric symptoms, including psychotic symptoms. The scale has 16 items, and each item can be defined on a seven-point scale varying from one (not present) to seven (extremely severe). Higher scores indicate more symptoms.</P>
<P>Hamilton Depression Rating Scale (HDRS) (<LINK REF="REF-Hamilton-1960" TYPE="REFERENCE">Hamilton 1960</LINK>) is designed to be used only on patients already diagnosed as suffering from affective disorder. The scale contains 17 or 21 variables measured on either a five-point or a three-point rating scale. Among the variables are: depressed mood, suicide, work and interests, retardation, agitation, gastrointestinal symptoms, general somatic symptoms, hypochondriasis, loss of insight, and loss of weight. Higher scores indicate more symptoms. </P>
<P>Positive and Negative Syndrome Scale (PANSS) (<LINK REF="REF-Kay-1991" TYPE="REFERENCE">Kay 1991</LINK>) is a 30-item schizophrenia scale, which is derived into three subscales for measuring the severity of general psychopathology, positive symptoms, and negative symptoms. Each item can be defined on a seven-point scoring system varying from one (absent) to seven (severe). Lower scores indicate lesser severity. </P>
<P>Scale for the Assessment of Negative Symptoms (SANS) (<LINK REF="REF-Andreasen-1982" TYPE="REFERENCE">Andreasen 1982</LINK>) is a six-point scale that gives a global rating of the following negative symptoms: alogia, affective blunting, avolition-apathy, anhedonia-asociality, and attentional impairment. Higher scores indicate more symptoms.<BR/> <BR/>Social functioning scales<BR/>Social Functioning Scale (SFS) (<LINK REF="REF-Birchwood-1990" TYPE="REFERENCE">Birchwood 1990</LINK>) is assessing areas of functions that are crucial for the community maintenance of individuals with schizophrenia. The seven areas are social engagement/withdrawal, interpersonal behaviour, pro-social activities, recreation, independence-competence, independence-performance and employment/occupation. The range of total scores is from 418 (poor) to 944.5 (optimal).</P>
<P>Treatment satisfaction scales<BR/>Drug Attitude Inventory (DAI-10) (<LINK REF="REF-Hogan-1983" TYPE="REFERENCE">Hogan 1983</LINK>) is a self-report 10-item scale for assessing patient satisfaction with antipsychotic treatment. Each item is rated one (does not favour drug) or two (favours drug). The range of a total score is 10-20. Higher scores indicate a more favourable attitude towards antipsychotic drug treatment.</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY>
<P>Randomisation and blinding<BR/>All included studies described themselves as randomised, but presented little methodological detail to elaborate on the truly random nature of allocation. One study had used the method of a block-randomisation (four patients per block) to ensure equal numbers in each centre (<LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>). Only one study (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>) described a truly random method of allocation (computer generated randomisation). Apart from this study, no other studies described a method that would prevent foreknowledge of allocation (i.e. person allocating treatment different from person recruiting patients - preferably contacted by phone). </P>
<P>None of the included studies described how true blinding was ensured. <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK> was the only one to describe one aspect of blinding method, which was the use of a double-blind, double-dummy protocol, implying that tablets were identical in appearance and dosage schedule. Only one study (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>) described using a separate experimenter to record patient outcome ratings from the person manipulating dosage and monitoring progress. </P>
<P>Apart from one study (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>), all other studies were therefore located in the quality category B (randomised but concealment of allocation unclear). In more than half of the studies, the numbers of patients allocated to each treatment group were identical. When allocating by chance this is improbable unless block randomisation has been used. Apart of one description (<LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>), the studies did not comment on this.</P>
<P>Data reporting and analysis<BR/>As studies frequently presented data on graphs and by p-values, raw data were not always available for synthesis. SDs were not routinely reported in all studies. Only three studies (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>, <LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>) reported the data on the dropouts clearly. The method of 'last observation carried forward' was declared in three studies (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>, <LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>). It remained unclear if the studies had used a true 'intention to treat analysis', as numbers of patients in the final analysis (when reported) rarely matched those reported at baseline. Studies with crossover design did not provide data for the first phase of the study.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS>
<P>The search<BR/>The search strategy and correspondence with authors and pharmaceutical companies yielded 22 reports of eight separate trials judged to fulfil the inclusion criteria of randomised controlled trials. Biological Abstracts/BIOSIS, MEDLINE and CENTRAL were the most useful electronic databases to detect the included studies. Details of the results of individual databases are given below.</P>
<P>The Cochrane Schizophrenia Group's register found 92 records, and CENTRAL identified 95 publications. The searches of other electronic databases identified the following number of records: Biological Abstracts/BIOSIS 348 records, EMBASE 303, MEDLINE 105, PsycLIT/PsycINFO 33 records and LILACS eight records. After independently screening the searches, altogether 89 possible citations were identified. Based on evaluation of the full reports of the studies, eight trials (22 papers) were included in the review. Most of the excluded studies were non-randomised, open studies. According to the study protocol, the studies comparing clozapine with conventional antipsychotic drugs or with placebo were beyond this review and are (<LINK REF="REF-Wahlbeck-1999" TYPE="REFERENCE">Wahlbeck 1999</LINK>) or will be included in further Cochrane reviews.</P>
<P>Mortality<BR/>Data on mortality was missing in almost all of the studies. One paper (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>) and personal communication from the authors of another study (<LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>) revealed no deaths in the study sample. Two studies (<LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK>, <LINK REF="STD-Risperidone-1999" TYPE="STUDY">Risperidone 1999</LINK>) enabled us to conclude indirectly no deaths to have occurred, while all the participants had completed an assigned treatment.</P>
<P>Global Impression<BR/>Only one medium term study (<LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>) stated the number of patients with no clinical improvement/deterioration by CGI criteria (180 patients, RR 0.73, CI 0.47 to 1.13). Thus, there was no significant difference between newer atypical drugs and clozapine. There was no significant difference between the groups not ready for hospital discharge, either (one study, 20 patients, RR 0.49, CI 0.12 to 1.95). The effect of treatment was almost equal both in the new atypical and clozapine groups for CGI endpoint scores (four studies, 315 patients, WMD -0.10, CI -0.34 to 0.15). In <LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>, global assessment of functioning slightly favoured newer atypical drugs (one study, 19 patients, WMD -9.00, CI -18.44 to 0.44). The small sample size and extremely wide confidence intervals made this trend difficult to interpret so far. </P>
<P>Mental state<BR/>Five studies (<LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK>, <LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>, <LINK REF="STD-Risperidone-1999" TYPE="STUDY">Risperidone 1999</LINK>, <LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>) gave response rates by reduction of PANSS or BPRS scores. According to the criterion of less than 20% decrease in the total score, 81 out of 178 patients (46%) in the newer atypical group and 83 out of 173 patients (48%) in the clozapine group were not improved (351 patients, RR 0.93, 0.75 to 1.16). Deterioration in mental state or relapses did not show any superiority of either drug (six studies, 631 patients, RR 1.04, CI 0.79 to 1.38). </P>
<P>The effect of treatment was almost equal both in the new atypical and clozapine groups for negative and positive symptoms (pooling together either PANSS negative subscale or SANS: four studies, 310 patients, SMD -0.13, CI -0.36 to 0.09; pooling of BPRS positive symptoms or PANSS positive subscale: three studies, 134 patients, SMD 0.18, CI -0.16 to 0.52). In the symptom rating scales BPRS and PANSS, wide confidence intervals in most cases made these statistics difficult to interpret (BPRS: three studies, 198 patients, WMD 3.64, CI -0.56 to 7.83; PANSS: three studies, 281 patients, WMD -0.95, CI -6.99 to 5.08). After pooling together data either from BPRS or PANSS to form a psychosis symptoms rating scale, we found that there was no indication of a significant superiority of either clozapine or new atypical drugs (six studies, 479 patients, SMD 0.07, CI -0.11 to 0.26). </P>
<P>Depression was analysed in one study (<LINK REF="STD-Risperidone-1999" TYPE="STUDY">Risperidone 1999</LINK>), but the data did not meet our standard to be included into the meta-analysis, and it was entered into the software separately. The study drug comparisons did not find any significant differences on two measures of HDRS. In the clozapine but not in the risperidone group, however, there was a significant decrease in the depression scores between baseline and endpoint (35% and 16%, respectively). </P>
<P>Acceptability of treatment<BR/>Acceptability of treatment was measured by two separate measures: (1) leaving the study early (dropouts); and (2) patient dissatisfaction. Different sources (personal information from the patients, rating scale data) were used to get dichotomous data for the evaluation of patient dissatisfaction. Patients on clozapine showed a trend to drop out more easily, but it is difficult to interpret whether one or the other drug was superior (six studies, 624 patients, RR 0.91, CI 0.71 to 1.16). The general drop-out rate was high, approximately 28%. In the study with the highest drop-out rate (<LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>), 40% of the patients dropped out but this was not further commented on. One the other hand, in studies assessing patient dissatisfaction, patients with newer atypical drugs showed a trend to be less satisfied (three studies, 236 patients, RR 1.19, CI 0.66 to 2.13), but again, it is difficult to tell whether one or the other drug was superior or whether there was in fact no difference. </P>
<P>Cognitive functioning<BR/>There was no clear difference between newer atypical drugs and clozapine in the following measures to study cognitive functioning: dichotomous SKT memory scores in <LINK REF="STD-Remox_x002f_Risp_x002f_Zote-1996" TYPE="STUDY">Remox/Risp/Zote 1996</LINK> (135 patients, RR 0.70, CI 0.40 to 1.22), cognitive problems in <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK> (concentration difficulties: 86 patients, RR 0.64, CI 0.27 to 1.49; memory problems: 86 patients, RR 0.60, CI 0.29 to 1.22), and KAI intelligence scores in <LINK REF="STD-Remoxipride-1994" TYPE="STUDY">Remoxipride 1994</LINK> (34 patients, WMD -7.00, CI -19.12 to 5.12). Due to skewed distribution, continuous SKT data of the same study (<LINK REF="STD-Remoxipride-1994" TYPE="STUDY">Remoxipride 1994</LINK>) were not entered into the meta-analysis: no significant differences were found between the groups.</P>
<P>Social functioning<BR/>Social functional level was evaluated in one study (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>). Patients on newer atypical medication had better social functional level than those on clozapine (19 patients, WMD -47.00, CI -93.55 to -0.45). </P>
<P>Treatment satisfaction<BR/>Treatment satisfaction, measured by DAI-10 (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>), did not show any significant difference between the groups (19 patients, WMD 0.10, CI -2.57 to 2.77). </P>
<P>Adverse effects<BR/>Data extraction was complicated by variability in reporting the side effects. <LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK> did not report on adverse effects, and <LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK> did not measure adverse effects in detail; the latter group explained the decision had been made to retain blindness of the rater. </P>
<P>All studies other than <LINK REF="STD-Olanzapine-2000" TYPE="STUDY">Olanzapine 2000</LINK> and <LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK> provided us with information on extrapyramidal symptoms. However, the data were heterogeneous due to the other olanzapine study (<LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>). When this study was excluded, the homogenous results indicated movement disorders be more common in patients with newer atypical medication (mainly risperidone) than with clozapine (five studies, 305 patients, RR 3.55, CI 1.79 to 7.06, NNT 6, CI 4 to 9). In the six included studies, 16% of the patients in the newer atypical group (23% of the patients if the olanzapine study is excluded) and eight per cent of patients in the clozapine group exhibited extrapyramidal symptoms. Continuous data on extrapyramidal symptom scales were not unequivocal regarding normal distribution in three studies (<LINK REF="STD-Risperidone-1999" TYPE="STUDY">Risperidone 1999</LINK>, <LINK REF="STD-Remox_x002f_Risp_x002f_Zote-1996" TYPE="STUDY">Remox/Risp/Zote 1996</LINK>, <LINK REF="STD-Remoxipride-1994" TYPE="STUDY">Remoxipride 1994</LINK>), and the data were not entered into the meta-analysis. The findings of these studies were parallel to the dichotomous EPS data. </P>
<P>The patients with clozapine suffered more from fatigue (one study, 86 patients, RR 0.55, CI 0.31 to 0.96, NNH 4, CI 2 to 31), nausea (two studies, 266 patients, RR 0.42, CI 0.19 to 0.92, NNH 12, CI 7 to 83), and orthostatic dizziness (two studies, 266 patients, RR 0.35, CI 0.15 to 0.85, NNH 12, CI 7 to 59). There was no clear difference between the groups in libido decrease (one study, 86 patients, RR 2.00, CI 0.39 to 10.35). In the olanzapine study with 180 patients (<LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>), hypersalivation was more common in the clozapine group (RR 0.08, CI 0.02 to 0.31, NNH 4, CI 3 to 6), whereas dry mouth (hyposalivation) showed a trend to be more common in the newer atypical group (RR 9.00, CI 0.49 to 164.77). One study (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>) declared that no seizures had occurred in either group (19 patients, RR 1.10, CI 0.02 to 50.43). Hypersomnia showed a trend to be more common in patients with clozapine (two studies, 266 patients, RR 0.65, CI 0.39 to 1.07). There was a similar trend favouring newer atypical drugs in sedation/drowsiness (two studies, 105 patients, RR 0.63, CI 0.36 to 1.09), and clozapine in insomnia (one study, 86 patients, RR 2.00, CI 0.53 to 7.49). No significant difference was found in weight gain (one study, 86 patients, RR 0.62, CI 0.32 to 1.22). Two studies reported on body weight changes (<LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>), in which the increase in body weight was higher in the clozapine group than in the newer atypical group (1.1 kg versus 2.7 kg, and 1.8 kg versus 2.3 kg, respectively). </P>
<P>Four studies (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>, <LINK REF="STD-Olanzapine-1998" TYPE="STUDY">Olanzapine 1998</LINK>, <LINK REF="STD-Risperidone-1998a" TYPE="STUDY">Risperidone 1998a</LINK>, <LINK REF="STD-Risperidone-1998b" TYPE="STUDY">Risperidone 1998b</LINK>) reported on blood reactions: white cell problems were encountered in five out of 277 patients using newer atypical drugs (four patients in the risperidone group and one patient in the olanzapine group), and in seven out of 281 patients in the clozapine group. The data showed no difference (558 patients, RR 0.76, CI 0.27 to 2.18). Agranulocytosis was commented on in only one study (<LINK REF="STD-Risperidone-2000" TYPE="STUDY">Risperidone 2000</LINK>); none were found. </P>
<P>Other outcomes<BR/>No data were available on quality of life, inability to work, family burden, or pharmacoeconomics. </P>
<P>Sensitivity analyses<BR/>Due to the limited amount of studies and inconsistency in reporting the results, sensitivity analyses were not undertaken for this version of the review.</P>
<P>Publication bias<BR/>Due to the limited number of studies, funnel graphs were not constructed for this review.</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION>
<P>General comments<BR/>Surprisingly few studies were found and included studies were generally of short duration, small (underpowered) and failed to report many outcomes in sufficient detail to allow pooling of all possible data. When this was possible, for some outcomes of interest, wide confidence intervals were obtained, making it difficult to know whether there was in fact any real difference between clozapine and other atypical drugs or whether they were the same in these respects. There was a poor consideration of statistical power on the part of the authors. It was difficult to know whether the studies had been designed to demonstrate equivalence between the two compounds or whether the authors set out to demonstrate a real difference on many clinically important outcomes.<BR/> <BR/>It is clear that most of the studies are 'efficacy' studies that allow us to say little about the comparative 'effectiveness' of these drugs as they might be used in routine clinical practice. Clinically important outcomes were not collected and the absence of any information on the quality of life and service use amongst patients is unfortunate.</P>
<P>Generalisability of findings<BR/>Surprisingly, the review identified only eight studies, and three of them were short in duration (four to six weeks). All studies were performed in patients with schizophrenia, and in five trials the patients with treatment resistant disease comprised the target group. The results are applicable to people with schizophrenia in a short duration of drug use, but they are not generalisable for other patient populations or for longer use of these drugs. Most patients receiving atypical drugs were treated either by risperidone or olanzapine, and this limits the generalisability of findings to the users of other newer atypical antipsychotic drugs.</P>
<P>In most of the included studies the setting was not reported clearly. One might assume that the first part of the study was undertaken at the hospital. If this assumption is correct, the trials report very little about treatment in the environment of the patients' everyday life. The diagnostic criteria of the studies were based on either DSM or ICD classification. Rigid inclusion criteria ensure internal consistency, but will exclude many of the patients who might receive these drugs in routine clinical practice and will reduce the 'real world' external validity of the study results.</P>
<P>To compare the newer atypical drugs as a group with clozapine, we pooled the data of all individual atypical drugs together. This approach is problematic, because newer antipsychotic drugs do have different profiles of action and various adverse effects. As the drugs are not similar to each other, caution is needed in extrapolating the results from the pooled data to individual drugs. One of our sensitivity analyses in the next versions of the review will be to look at the individual drugs in comparison to clozapine. </P>
<P>Reporting on concealment of allocation<BR/>Randomisation and blindness were not well reported and the completeness of these procedures cannot be assumed. The studies usually declared only randomisation and double-blind protocol but did not report how these procedures were performed. </P>
<P>Double-blindness might be difficult to achieve, given the need for routine blood monitoring amongst those receiving clozapine. The authors might need to demonstrate how this was achieved in the day-to-day running of the trial. For example, it would be important for the assessor to be different from the person in charge of the day-to-day management of the patient who monitors symptoms and adverse effects, because the person monitoring treatment is likely to be quite aware of which treatment the patient is receiving. Unfortunately, this is not possible in most of the industry-sponsored trials where it is usually the same clinician who takes care of the patients and the trial monitoring. The achievement of double-blindness cannot be assumed if the authors fail to report how it is achieved, given the logistical difficulties outlined above. It might be that double-blindness is an aspiration rather than an achievable goal, and a more honest approach might be to acknowledge this fact.</P>
<P>Mortality<BR/>Mortality was reported in only one paper. Additional information from one study and indirect evidence from two papers revealed that neither atypical group nor clozapine group had experienced any deaths during the follow-up. The infrequency of this statistic and the lack of any statistical power (despite meta-analytic pooling) to detect a real difference is noted.</P>
<P>Global impression<BR/>As the number of trials is very limited so far, the suggestions about the efficacy of newer atypical antipsychotic drugs can be only very preliminary. Newer atypical drugs seem to be broadly similar to clozapine when improvement is measured using a global index. Caution needs to be applied in that this result was only obtained from four studies and relatively small number of patients. </P>
<P>Mental state<BR/>There was a trend for clozapine to be more effective than the comparators for positive symptoms, but less effective than the comparators for negative symptoms; however, statistical significance for these effects was not reached. Other measures of clinical improvement were not statistically significant, either to show whether there is any real difference between clozapine and other atypical drugs, or whether the drugs are in fact equivalent. As the number of trials is increased and more drugs are investigated, we might hope that a clearer picture would emerge, with greater statistical confidence.</P>
<P>Acceptability of treatment<BR/>No difference in acceptability between clozapine and new atypical drugs, as measured by number of study dropouts or number of satisfied patients, was evident. This is somewhat surprising, because clozapine has more adverse effects than the new comparator drugs. Future sensitivity analyses will show if there are differences in acceptability of drugs in certain subgroups.</P>
<P>Social functioning<BR/>Patients on new atypical medication (risperidone) had better social functional level than those on clozapine. This result, however, was obtained from a small study, and needs replication in larger studies of longer duration. <BR/> <BR/>Adverse effects<BR/>Adverse effect profiles were different in clozapine versus newer atypical drugs. Clozapine produced markedly more fatigue, hypersalivation, nausea, and orthostatic dizziness. The atypical drugs were heterogeneous in their ability to generate extrapyramidal symptoms. There was no statistical difference between clozapine and olanzapine in this aspect, but the other included new atypical drugs (mainly risperidone) caused more motor disturbances than clozapine.</P>
<P>Treatment-resistant or first-episode schizophrenia<BR/>As the studies were performed with schizophrenia and mostly its treatment resistant form, it is not possible to predict if the results are applicable to patients with their first psychosis. </P>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>These few studies lend guarded support to the arrival of newer atypical antipsychotic drugs on the market. However, the data on the efficacy of these drugs display statistical uncertainty surrounding many of the major comparative endpoints which would influence clinical practice and policy. We cannot tell from these data whether clozapine is inferior, superior or equivalent to other atypical drugs in its ability to improve mental state. More research is needed to improve the power and precision of these estimates of clinical efficacy. The short-term nature of these studies and the absence of many clinically meaningful endpoints limit the application of the results of these studies to the routine day-to-day care of patients with schizophrenia, as encountered in routine clinical practice.</P>
<P>The adverse effect profile of the newer atypical antipsychotics is different from that of clozapine, and these newer atypical drugs may also slightly differ from one another. For people with schizophrenia, the new drugs offer alternatives, both for chronic and first-line use, whereas clozapine has been designated to be available only for those with drug-resistant disease, so far. For clinicians, the new drugs are potentially promising products, particularly if clinical equivalence and acceptability are demonstrated with clozapine. If they were to be equally effective and acceptable, whilst not requiring the weekly blood tests of clozapine, then they will form an important treatment option. The limited data do not allow us to demonstrate this clinical equivalence and equal acceptability with statistical certainty. Most importantly, the research allows us to say little about the impact of these drugs on the quality of patients' life, long term compliance, longer-term outcome and service use. </P>
<P>Managers, governments and health policy makers will be aware that the pharmaceutical industry is currently marketing the new atypical drugs very heavily and is seeking to broaden the indications for clinical use to include first-line treatment for schizophrenia and treatment for those not responsive to typical antipsychotics. The effectiveness of clozapine in treatment-resistant schizophrenia is suggested by a concurrent systematic review in this library (<LINK REF="REF-Wahlbeck-1999" TYPE="REFERENCE">Wahlbeck 1999</LINK>). Even this large review has limited data as studies were largely short, conducted in an inpatient setting, and do not report important clinical endpoints such as quality of life, social functioning, long term compliance and service use. </P>
<P>If this review were to demonstrate equivalent efficacy and tolerability to clozapine, without the need for weekly blood tests, then we might conclude that new atypical drugs were a significant new 'health technology' or innovation. Unfortunately, this review does not allow this conclusion to be reached with certainty. Further, the absence of quality of life data or meaningful economic evaluation in the studies reviewed makes it difficult to give guidance as to whether investment in these drugs would produce significant impact on the care of those with schizophrenia. </P>
<P>The unit costs of these new drugs should not be the only factor to guide their use. Increased cost might be justified if they resulted in 'sufficient benefit'. Unfortunately, decision makers might feel that 'sufficient benefit' is not demonstrated in this case - the research is not designed in such a way as to demonstrate this benefit. Investment in these drugs would represent a major 'opportunity' cost in terms of the other competing interventions that might be forgone to fund their introduction. Clinicians, policy makers and patients alike might feel the need to demand better quality research evidence before endorsing the widespread use of these drugs.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>Methodology<BR/>More trials are clearly needed to assess the advantages and disadvantages of each atypical drug in comparison to clozapine. Trials need to be of longer duration to find out the drug effect on both the acute symptoms and on the chronic illness and its impact on a person's life. Concurrent prospective economic evaluations are required to inform the cost implications (costs and potential savings) of these drugs in clinical practice.</P>
<P>Randomisation and blinding<BR/>Concealment of allocation, randomisation process and blinding should be conducted in a rigorous manner and reported sufficiently to allow the critical reader to be sure that each of these potential sources of bias are adequately dealt with. The difficulties in achieving double-blindness in these trials is outlined above and a more honest acknowledgement of these problems will lead to more rigorous and believable research evidence. This is a complex logistical difficulty, which the clinical and economic importance of the problem requires be solved in an open manner.</P>
<P>Participants<BR/>The studies should be planned to cover a special target population of schizophrenia (drug resistant schizophrenia, different types of schizophrenia, first psychosis, child and adolescent psychotic symptoms etc.) to give information on the results in each subgroup of patients. As newer atypical drugs are thought to be effective on negative symptoms, to rule out the effect of comorbid depression this should be evaluated by separate rating scales of mood disorders. Broader (less rigid) inclusion criteria would allow the results of research to be more readily generalisable to routine practice.</P>
<P>Interventions<BR/>Newer atypical drugs should be evaluated by trying to find a profile of each drug to get to know the similarities and differences of these drugs and to be able to choose a most suitable drug for each patient. In addition to comparisons with clozapine, additional comparative studies between individual atypical drugs should be undertaken.</P>
<P>Setting<BR/>The studies usually do not inform whether the trial is performed at the hospital or at the outpatient clinic. At least the studies of longer duration should extend to the patient's own environment where the effect and limitations caused by the drug will be more clearly seen. </P>
<P>Outcome measures<BR/>Trialists should be encouraged to use widely accepted rating scales, with acceptable validity and reliability. Symptom rating scales encourage researchers to report data on a continuous form, but rating scales that evaluate adverse effects are often not normally distributed and have to be ignored by the software statistics so far. Where possible, the use of dichotomous outcome measures, in preference to continuous scales, is to be encouraged. It is noted that the continuous outcome measures used are not generally used in routine clinical practice and it is therefore difficult to know how much of this research applies to the routine day to day care of patients. Dichotomous outcomes, such as relapse, discontinuation, and readmission may be of more direct relevance to clinicians and policy makers and will be more easily understood. These outcome measures could be collected at no extra cost to experimenters and might in fact be preferable to complex continuous scales. The collection and reporting of these dichotomous measures are to be encouraged. </P>
<P>Withdrawals<BR/>Reasons for discontinuation should be reported in detail. The occurrence or lack of deaths and serious or life-threatening adverse effects such as agranulocytosis should routinely be reported. 'Intention to treat' analysis should be undertaken and reported in sufficient detail to allow the reader to be sure that it is in fact what took place. 'Last observation carried forward' or other methods should be used to include the patient data of as many participants as possible into the endpoint data analysis. Again, numbers should be reported. </P>
<P>Adverse effects<BR/>Adverse effect profile is likely to affect longer-term compliance and quality of life. The absence of quality of life measures and important aspects of service use such as relapse and readmission are regrettable. Similarly, the inclusion of such outcome measures would allow meaningful economic evaluation to be presented.</P>
<P>Presentation of data<BR/>Data should preferably be presented in tables with means and standard deviations and including the actual number of patients studied. In cases where binary outcomes can be used, these should be encouraged, provided that the relevant cut-off points can be presented. Although the data change between baseline and endpoint stages would be informative, endpoint scores should be preferred to make interstudy comparisons more accessible.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>We would like to thank Dr Stefan Leucht and the anonymous editor for helpful comments, and the editorial staff at the Cochrane Schizophrenia Group for practical help and support. Librarian Anja Roilas and Dr Seppo Kähkönen at the Department of Psychiatry, University of Helsinki, the staff of the Biomedical Library, University of California San Diego, USA, and National Library of Health Sciences, University of Helsinki, Finland are acknowledged in obtaining the articles. We thank Dr Aldemar Araujo Castro and the staff of the Brazilian Cochrane Centre for additional literature searches. The following authors and pharmaceutical companies who provided us with further information on their trials are acknowledged: Dr J-N Beuzen, Dr G Bondolfi, Dr PF Buckley, Dr B Eikelmann, Dr C Schormair, Astra, Eli Lilly, Hoechst Marion Roussel, Janssen-Cilag, Zeneca.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2008-10-29 15:54:39 +0000" MODIFIED_BY="[Empty name]">
<P>Arja Tuunainen has received grants from some pharmaceutical companies for travel to international meetings (including Zeneca, manufacturer of quetiapine).</P>
<P>Kristian Wahlbeck has received grants from several pharmaceutical companies for travel to international meetings (including Janssen-Cilag, manufacturer of risperidone, and Pfizer, manufacturer of ziprasidone).</P>
<P>Simon Gilbody - none known.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Arja Tuunainen - initiated the study, wrote the initial protocol, conducted several of the literature database searches, screened studies for inclusion, extracted data from included studies, contacted study authors and pharmaceutical companies, entered data into RevMan and wrote the report. Arja Tuunainen is the guarantor of the review.</P>
<P>Kristian Wahlbeck - collaborated on the study first as a key editor, then as a co-author, commented on the initial protocol, conducted several of the literature searches, screened studies for inclusion, extracted data from studies and co-authored final drafts of the recent report.</P>
<P>Simon Gilbody - collaborated on the study, commented on the initial protocol, conducted several of the literature searches, screened studies for inclusion, extracted data from studies and co-authored final drafts of the report.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES>
<P>Cochrane Schizophrenia Group internal peer review complete (see Module).<BR/>External peer review scheduled.</P>
</PUBLIC_NOTES>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2008-10-29 16:35:54 +0000" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2008-10-29 16:29:31 +0000" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2008-10-29 16:29:31 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="MIX" ID="STD-Olanzapine-1998" NAME="Olanzapine 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Beasley CM Jr, Beuzen J-N, Birkett MA, Kiesler GM, Tollefson GD, Wood AJ</AU>
<TI>Olanzapine versus clozapine: an international double-blind study of the treatment of resistant schizophrenia</TI>
<SO>Proceedings of the American Psychiatric Association 152nd Annual Meeting; 1999 May 15-20; Washington, DC, USA</SO>
<YR>1999</YR>
<PG>136-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Beuzen JN, Birkett MA, Kiesler GM, Wood AJ</AU>
<TI>Olanzapine versus clozapine: a double-blind international study in the treatment of resistant schizophrenic patients</TI>
<SO>Proceedings of the 21st Collegium Internationale Neuro-Psychopharmacologicum Congress; 1998 July 12-16; Glasgow, UK</SO>
<YR>1998</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Olanzapine-2000" NAME="Olanzapine 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Oliemeulen EAP, van Hoof JJM; Jogems-Kosterman BJM, Hulstijn W, Tuynman-Qua HG</AU>
<TI>Is olanzapine a substitute for clozapine? The effects on psychomotor performance. Proceedings of the 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 6-11; Davos, Switzerland</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>187</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remox_x002f_Risp_x002f_Zote-1996" NAME="Remox/Risp/Zote 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heinrich K, Klieser E, Lehmann E, Kinzler E, Hruschka H</AU>
<TI>Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomized trial</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1994</YR>
<VL>18</VL>
<PG>129-37</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994159916"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heinrich K, Klieser E, Lehmann E, Kinzler E</AU>
<TI>Experimental comparison of the efficacy and compatibility of clozapine and risperidone in acute schizophrenia. Proceedings of the 18th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1992 June 28-July 2; Nice, France</TI>
<SO>Clinical Neuropharmacology</SO>
<YR>1992</YR>
<VL>15 Suppl 1</VL>
<NO>Part B</NO>
<PG>375B</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="CONFERENCE_PROC">
<AU>Heinrich K, Klieser E, Lehmann E, Kinzler E</AU>
<TI>Experimental comparison of the efficacy and compatibility of risperidone and clozapine in acute schizophrenia</TI>
<SO>Risperidone - major progress in antipsychotic treatment. Proceedings of a Satellite Symposium at the 17th Congress of Collegium Internationale Neuro-Psychopharmacologicum; 1991 Sep 10-13; Kyoto, Japan</SO>
<YR>1991</YR>
<PG>37-9</PG>
<ED>Kane JM</ED>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Heinrich K</AU>
<TI>Risperidone versus clozapine in acute schizophrenia</TI>
<SO>Proceedings of the 1st International Risperidone Investigators' Meeting; 1992 Mar 9-16; Paris, France</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Klieser E, Kinzler E</AU>
<TI>Risperidone versus clozapine in the treatment of schizophrenic patients with acute symptoms: a double-blind, randomized trial</TI>
<SO>Clinical Research Report on R64766 Ris-FRG-9005</SO>
<YR>1991</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="BOOK_SECTION">
<AU>Klieser E, Lehmann E, Heinrich K</AU>
<TI>Risperidone in comparison with various treatments of schizophrenia</TI>
<SO>Medicine psychiatry, Vol. 3. Serotonin in antipsychotic treatment: mechanisms and clinical practice</SO>
<YR>1996</YR>
<PG>331-43</PG>
<ED>Kane JM, Möller H-J, Awouters F</ED>
<PB>Marcel Dekker</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Lehmann E, Kinzler E, Wurthmann C, Heinrich K</AU>
<TI>Randomized, double-blind, controlled trial of risperidone versus clozapine in-patients with chronic schizophrenia</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1995</YR>
<VL>15 Suppl 1</VL>
<PG>45S-51S</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1995247943"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Rappard F</AU>
<TI>Randomized, double-blind, controlled trial of risperidone versus clozapine in patients with acute exacerbations of schizophrenia. Proceedings of the 7th Congress of the Association of European Psychiatrists; 1994 Sep 18-22; Copenhagen, Denmark</TI>
<SO>European Psychiatry</SO>
<YR>1994</YR>
<VL>9 Suppl 1</VL>
<PG>154S</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Klieser E, Strauss WH, Burtscheid W</AU>
<TI>Double-blind comparative study of haloperidol, remoxipride and clozapine in schizophrenia</TI>
<SO>Proceedings of the 15th Collegium Internationale Neuro-Psychopharmacologicum Congress; 1986 Dec 14-17; San Juan, Puerto Rico</SO>
<YR>1986</YR>
<PG>111</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Strauss WH</AU>
<TI>Quasi-experimental comparison of the efficacy of classical and atypical neuroleptics in acute schizophrenia with respect to their cognitive and emotional side effects. Proceedings of the 18th Symposium of AGNP; 1993; Nuremberg, Germany</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1993</YR>
<VL>26</VL>
<PG>168</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Remoxipride-1994" NAME="Remoxipride 1994" YEAR="1994">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klieser E, Strauss WH, Lemmer W</AU>
<TI>The tolerability and efficacy of the atypical neuroleptic remoxipride compared with clozapine and haloperidol in acute schizophrenia</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1994</YR>
<VL>89 Suppl 380</VL>
<PG>68-73</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1994324291"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Risperidone-1998a" NAME="Risperidone 1998a" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bondolfi G, Baumann P, Dufour H</AU>
<TI>Treatment-resistant schizophrenia: clinical experience with new antipsychotics</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>S2-21-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996384220"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bondolfi G, Baumann P, Patris M, May JP, Billeter U, Dufour H</AU>
<TI>A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia (abstract). Proceedings of the 8th European College of Neuropsychopharmacology Congress; 1995 Sep 30-Oct 4; Venice, Italy</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1995</YR>
<VL>5</VL>
<PG>349</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Bondolfi G, Baumann P, Patris M, May JP, Billeter U, Dufour H</AU>
<TI>A randomized double-blind trial of risperidone versus clozapine for treatment resistant chronic schizophrenia (abstract)</TI>
<SO>Proceedings of the American Psychiatric Association 148th Annual Meeting, 1995 May 20-25; Miami, USA</SO>
<YR>1995</YR>
<PG>185</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Bondolfi G, Dufour H, Patris M, May JP, Billeter U, Eap CB, et al</AU>
<TI>Risperidone versus clozapine in treatment-resistant chronic schizophrenia: a randomized double-blind study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1998</YR>
<VL>155</VL>
<PG>499-504</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Risperidone-1998b" NAME="Risperidone 1998b" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Anand R, Alphs L, Azorin JM, Remington G, Péré J-J, Bourdeix I</AU>
<TI>Superior efficacy of clozapine in chronic, severe schizophrenia: comparison with risperidone</TI>
<SO>Highlights. Treatment-resistant schizophrenia and beyond. Current concepts and future prospects; 1998 July 8-9; London, UK</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Risperidone-1999" NAME="Risperidone 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Breier AF, Malhotra AK, Su T-P, Pinals DA, Elman E, Adler CM, et al</AU>
<TI>Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine responses</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<PG>294-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Risperidone-2000" MODIFIED="2008-10-29 16:29:31 +0000" MODIFIED_BY="[Empty name]" NAME="Risperidone 2000" YEAR="2000">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cheine MV, Wahlbeck K, Tuisku K, Joffe G</AU>
<TI>Risperidone versus clozapine in the treatment of neuroleptic-refractory/intolerant schizophrenia patients: a single-blind randomized trial. Preliminary report of an on-going study. Proceedings of the 38th Annual Meeting of the Scandinavian Society for Psychopharmacology; 1997 Apr 9-11; Copenhagen, Denmark</TI>
<SO>Nordic Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>51</VL>
<PG>99</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-29 16:29:31 +0000" MODIFIED_BY="[Empty name]" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Wahlbeck K, Cheine M, Tuisku K, Ahokas A, Joffe G, Rimón R</AU>
<TI>Risperidone versus clozapine in treatment-resistant schizophrenia: a randomized pilot study</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>2000</YR>
<VL>24</VL>
<NO>6</NO>
<PG>911-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2008-10-29 16:19:56 +0000" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Busatto-1995" NAME="Busatto 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Busatto GF, Pilowsky LS, Costa DC, Ell PJ, Verhoeff NPLG, Kerwin RW</AU>
<TI>Dopamine D-2 receptor blockade in vivo with the novel antipsychotics risperidone and remoxipride: an 123I-IBZM single photon emission tomgraphy (SPET) study</TI>
<SO>Psychopharmacology</SO>
<YR>1995</YR>
<VL>117</VL>
<PG>55-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cavallaro-1995" NAME="Cavallaro 1995" YEAR="1995">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Cavallaro R, Colombo C, Smeraldi E</AU>
<TI>A pilot, open study on the treatment of refractory schizophrenia with risperidone and clozapine</TI>
<SO>Human Psychopharmacology</SO>
<YR>1995</YR>
<VL>10</VL>
<NO>3</NO>
<PG>231-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chouinard-1994" NAME="Chouinard 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Beaudry P, Vainer J, Turnier L, Roy J-Y, Miller R</AU>
<TI>Risperidone and clozapine in the treatment of neuroleptic-induced supersensitivity psychosis. Proceedings of the 48th Annual Convention &amp; Scientific Program of the Society of Biological Psychiatry; 1993 May 19-23; San Francisco, USA</TI>
<SO>Biological Psychiatry</SO>
<YR>1993</YR>
<VL>33</VL>
<PG>130A</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Chouinard G, Vainer JL, Bélanger M-C, Turnier L, Beaudry P, Roy J-Y, et al</AU>
<TI>Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis</TI>
<SO>Progress in Neuro-Psychopharmacology and Biological Psychiatry</SO>
<YR>1994</YR>
<VL>18</VL>
<PG>1129-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Eikelmann-1997" NAME="Eikelmann 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Eikelmann B, Schormair C, Reker T</AU>
<TI>Pharmacotherapy of chronic schizophrenia - new developments. Proceedings of the World Psychiatric Association; 1997 Apr 23-26; Geneva, Switzerland</TI>
<SO>European Psychiatry</SO>
<YR>1997</YR>
<VL>12 Suppl 2</VL>
<PG>151S</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Flynn-1998" NAME="Flynn 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Flynn SW, MacEwan GW, Altman S, Kopala LC, Fredrikson DH, Smith GN, et al</AU>
<TI>An open comparison of clozapine and risperidone in treatment-resistant schizophrenia</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1998</YR>
<VL>31</VL>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Flynn SW, MacEwan GW, Altman S, Kopala LC, Smith GN, Honer WG</AU>
<TI>A comparison of two atypical antipsychotics in treatment resistant schizophrenia. Proceedings of the VIth International Congress on Schizophrenia Research, Colorado Springs; 1997 Apr 12-16; Colorado, USA</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>185</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallhofer-1996" NAME="Gallhofer 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Gallhofer B, Bauer U, Lis S, Krieger S, Gruppe H</AU>
<TI>Cognitive dysfunction in schizophrenia: comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>S2-13-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Honer-1998" NAME="Honer 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Honer WG, Kopala LC, Smith GN, Flynn SW, Fredrikson DH, Good KP, et al</AU>
<TI>A comparison of treatment response between early- and adult-onset schizophrenia. Proceedings of the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13; Davos, Switzerland</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<PG>162</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Klemm-1996" NAME="Klemm 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Klemm E, Gruenwald F, Kasper S, Menzel C, Broich K, Danos P, et al</AU>
<TI>(123I)IBZM SPECT for imaging of striatal D-2 dopamine receptors in 56 schizophrenic patients taking various neuroleptics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>183-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konrad-1996" NAME="Konrad 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Konrad C, Schormair C, Eikelmann B, Berger K, Rottmann P</AU>
<TI>Clozapine and risperidone in the treatment of therapy-resistant schizophrenia: a preliminary report on two ongoing clinical trials</TI>
<SO>Proceedings of the 8th Congress of the Association of European Psychiatrists; 1996 July 7-12; London, UK</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Konrad-1997" NAME="Konrad 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Konrad C, Schormair C, Knickelbein U, Ophaus P, Eikelmann B</AU>
<TI>Risperidone and clozapine in pharmaco-resistant schizophrenia</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>5</NO>
<PG>190</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Konrad C, Schormair C, Ophaus P, Knickelbein U, Eikelmann B</AU>
<TI>Clozapine versus risperidone in pharmaco-refractory schizophrenia: a preliminary report</TI>
<SO>Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, CA, USA</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kufferle-1997" NAME="Kufferle 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kufferle B, Tauscher J, Asenbaum S, Vesely C, Podreka I, Brucke T, et al</AU>
<TI>IBZM SPECT imaging of striatal dopamine-2 receptors in psychotic patients treated with the novel antipsychotic substance quetiapine in comparison to clozapine and haloperidol</TI>
<SO>Psychopharmacology</SO>
<YR>1997</YR>
<VL>133</VL>
<PG>323-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kumra-1998" NAME="Kumra 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Kumra S, Jacobsen LK, Lenane M, Karp BI, Frazier JA, Smith AK, et al</AU>
<TI>Childhood-onset schizophrenia: an open-label study of olanzapine in adolescents</TI>
<SO>Journal of American Academy of Child and Adolescent Psychiatry</SO>
<YR>1998</YR>
<VL>37</VL>
<PG>377-85</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindenmayer-1998" NAME="Lindenmayer 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Lindenmayer J-P, Iskander A, Apergi F-S, Park M</AU>
<TI>Cognitive profile and soft signs in clozapine versus risperidone treatment</TI>
<SO>Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, CA, USA</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer J-P, Iskander A, Park M, Apergi FS, Czobor P, Smith R, et al</AU>
<TI>Clinical and neurocognitive effects of clozapine and risperidone in treatment-refractory schizophrenic patients: a prospective study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>10</NO>
<PG>521-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindenmayer J-P, Iskander A, Park M, Smith R, Apergi F-S, Czobor P</AU>
<TI>Psychopathological and neuropsychological profile of clozapine versus risperidone in refractory schizophrenics. Proceedings of the 6th International Congress on Schizophrenia Research, Colorado Springs; 1997 Apr 12-16; Colorado, USA</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>195</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="OTHER">
<AU>Lindenmayer J-P, Park M, Iskander A, Bark NM, Smith RM, Cooper TB</AU>
<TI>Clozapine versus risperidone in treatment refractory state psychiatric inpatients</TI>
<SO>Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, USA</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meyer_x002d_Lindenberg1997" NAME="Meyer-Lindenberg1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallhofer B, Gruppe H, Bauer U</AU>
<TI>Zotepine versus clozapine: a comparison of the impact on the cognitive dysfunction syndrome in schizophrenia ( a double blind trial). Proceedings of the 19th Symposium of AGNP; 1995; Nuremberg, Germany</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1995</YR>
<VL>28</VL>
<PG>179</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallhofer B, Ulferts J, Bauer U, Gruppe H</AU>
<TI>Cognitive dysfunction in schizophrenia: a comparison of the impact of zotepine versus clozapine on the syndrom (a double blind trial)</TI>
<SO>Schizophrenia Reseach</SO>
<YR>1996</YR>
<VL>18</VL>
<NO>2-3</NO>
<PG>220</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meyer-Lindenberg A, Gruppe H, Bauer U, Lis S, Krieger S, Gallhofer B</AU>
<TI>Improvement of cognitive function in schizophrenic patients receiving clozapine or zotepine: results from a double-blind study</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<PG>35-42</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1997278431"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Naber-1997" NAME="Naber 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="CONFERENCE_PROC">
<AU>Naber D</AU>
<TI>Evidence of efficacy of neuroleptics in effective versus negative symptoms</TI>
<SO>Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nicolini-1997" NAME="Nicolini 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Nicolini H, Cruz C, Camarena B, Ortega H</AU>
<TI>5HT2A and DRD4 molecular genotypes in a clinical trial of olanzapine versus risperidone in schizophrenic patients</TI>
<SO>Proceedings of the 10th European College of Neuropsychopharmacology Congress; 1997 Sep 13-17; Vienna, Austria</SO>
<YR>1997</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pilowsky-1996" NAME="Pilowsky 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pilowsky LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundsson T, et al</AU>
<TI>Dopamine D-2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine: a 123I IBZM single photon emission tomography (SPET) study</TI>
<SO>Psychopharmacology</SO>
<YR>1996</YR>
<VL>124</VL>
<PG>148-53</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pilowsky-1997" NAME="Pilowsky 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Pilowsky LS, O'Connell P, Davies N, Busatto GF, Costa DC, Murray RM, et al</AU>
<TI>In vivo effects on striatal dopamine D-2 receptor binding by the novel atypical antipsychotic drug sertindole - a 123I IBZM single photon emission tomography (SPET) study</TI>
<SO>Psychopharmacology</SO>
<YR>1997</YR>
<VL>130</VL>
<PG>152-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rapoport-1997" NAME="Rapoport 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Rapoport J, Kumra S, Jacobsen LK</AU>
<TI>The spectrum of extrapyramidal symptoms in children and young adults</TI>
<SO>Proceedings of the 150th Annual Meeting of the American Psychiatric Association; 1997 May 17-22; San Diego, USA</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Robinson-1997" NAME="Robinson 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Robinson DG, Lieberman JA, Sheitman B, Alvir JMJ, Kane JM</AU>
<TI>Pilot study of atypical antipsychotic agents in first episode schizophrenia. Proceedings of the 6th International Congress on Schizophrenia Research; 1997 Apr 12-16; Colorado Springs, CO, USA</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>24</VL>
<PG>196</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sharif-1998" NAME="Sharif 1998" YEAR="1998">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Sharif ZA, Raza A, Ratakonda S, Kirschner T, Miller CE, Gorman JM</AU>
<TI>Comparative efficacy of clozapine and risperidone in treatment refractory schizophrenia</TI>
<SO>Schizophrenia Research</SO>
<YR>1998</YR>
<VL>29</VL>
<NO>1-2</NO>
<PG>147</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-1996" NAME="Su 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="OTHER">
<AU>Su TP, Elman I, Malhotra AK, Adler CM, Pickar D, Breier AF</AU>
<TI>Comparison of weight gain during risperidone and clozapine treatment in chronic schizophrenia</TI>
<SO>Proceedings of the 149th Annual Meeting of the American Psychiatric Association; 1996 May 4-9; New York, USA</SO>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tauscher-1999" NAME="Tauscher 1999" YEAR="1999">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tauscher J, Kufferle B, Asenbaum S, Fischer P, Pezawas L, Barnes C, et al</AU>
<TI>In vivo 123I IBZM SPECT imaging of striatal dopamine-2 receptor occupancy in schizophrenic patients treated with olanzapine in comparison to clozapine and haloperidol</TI>
<SO>Psychopharmacology</SO>
<YR>1999</YR>
<VL>141</VL>
<NO>2</NO>
<PG>175-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tauscher J, Kufferle B, Barnas C, Asenbaum S, Bruecke T, Kasper S</AU>
<TI>123I IBZM SPECT imaging of dopamine-2 receptors in psychotic patients treated with olanzapine, risperidone, clozapine and haloperidol</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1997</YR>
<VL>30</VL>
<NO>5</NO>
<PG>228</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Thompson-1996" MODIFIED="2008-10-29 16:19:56 +0000" MODIFIED_BY="[Empty name]" NAME="Thompson 1996" YEAR="1996">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Thompson D</AU>
<TI>Cost of switching from neuroleptics to risperidone and clozapine: a pilot study of the San Diego County Mental Health Services</TI>
<SO>Clinical Drug Investigation</SO>
<YR>1997</YR>
<VL>14</VL>
<PG>428-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2008-10-29 16:19:56 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Thompson D</AU>
<SO>Costs of treatment with risperidone and clozapine. Report submitted to the San Diego Department of Mental Health</SO>
<YR>1996</YR>
<CY>San Diego, California</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tran-1997" NAME="Tran 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Tran PV, Hamilton SH, Kuntz AJ, Potvin JH, Andersen SW, Beasley C Jr, et al</AU>
<TI>Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1997</YR>
<VL>17</VL>
<PG>407-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Travis-1997" NAME="Travis 1997" YEAR="1997">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Travis JM, Busatto GF, Pilowsky LS, Mulligan R, Gacinovic S, Acton P, et al</AU>
<TI>In vivo 5-HT2A receptor blockade in schizophrenic patients treated with the broad spectrum atypical antipsychotic clozapine and olanzapine: preliminary SPET findings</TI>
<SO>Journal of Nuclear Medicine</SO>
<YR>1997</YR>
<VL>38 Suppl 5</VL>
<PG>107P</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Daniel-1996" NAME="Daniel 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Allocation: crossover design, data on the first phase not available. Author contacted, no reply yet.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG, Goldberg TE, Weinberger DR, Kleinman JE, Pickar D, Lubick LJ, et al</AU>
<TI>Different side effect profiles of risperidone and clozapine in 20 outpatients with schizophrenia or schizoaffective disorder: a pilot study</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>153</VL>
<PG>417-9. Allocation: crossover design, data on the first phase not available. Author contacted, no reply yet</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1996180611"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG</AU>
<TI>Comparison of risperidone and clozapine on clinical and cognitive functions in psychotic disorders. Proceedings of the 49th Annual Convention &amp; Scientific Program of the Society of Biological Psychiatry; 1994 May 18-22; Philadelphia, USA</TI>
<SO>Biological Psychiatry</SO>
<YR>1994</YR>
<VL>35</VL>
<PG>667</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Daniel DG</AU>
<TI>Crossover comparison of risperidone and clozapine on clinical, cognitive, and side effect measures in treatment-resistant psychosis</TI>
<SO>Psychopharmacology Bulletin</SO>
<YR>1994</YR>
<VL>30</VL>
<PG>629</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Estrella-1996" NAME="Estrella 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;Allocation: unclear if open. Author contacted, no reply yet.&lt;/p&gt;" PRIMARY="YES" TYPE="OTHER">
<AU>Estrella MH, Soria LF, Gonzalez CJC, Butron MAL, Torres JA, Escareño R</AU>
<TI>Cost-effectiveness of clozapine versus respiridona for treatment-resistant schizophrenic patients</TI>
<SO>Proceedings of the Xth Congress of Psychiatry; 1996 Aug 23-28; Madrid, Spain</SO>
<YR>1996</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Su-1997" NAME="Su 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su T-P, Breier A, Coppola R, Hadd K, Elman I, Adler C, et al</AU>
<TI>D2 receptor occupancy in risperidone and clozapine-treated schizophrenics</TI>
<SO>Biological Psychiatry</SO>
<YR>1996</YR>
<VL>39</VL>
<PG>513-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Su T-P, Breier A, Coppola R, Hadd K, Elman I, Alder C, et al</AU>
<TI>D2 receptor occupancy during risperidone and clozapine treatment in chronic schizophrenia: relationship to blood level, efficacy and EPS. Proceedings of the 26th Annual Meeting of the Society for Neuroscience; 1996 Nov 16-21; Washington, D.C., USA</TI>
<SO>Society for Neuroscience Abstracts</SO>
<YR>1996</YR>
<VL>22</VL>
<PG>265</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE NOTES="&lt;p&gt;Allocation: crossover design, data on the first phase not available. Author contacted, no reply yet.&lt;/p&gt;&lt;p&gt;Allocation: crossover design, data on the first phase not available. Author contacted, no reply yet.&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Su T-P, Malhotra AK, Hadd K, Breier A, Pickar D</AU>
<TI>D2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1997</YR>
<VL>54</VL>
<PG>972-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</AWAITING_STUDIES>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="MIX" ID="STD-Lewis-2000" NAME="Lewis 2000" YEAR="Lewis">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Lewis SW, Davies L, Jones P, Kerwin R, Barnes TRE, Murray RM, et al</AU>
<TI>The CutLASS study: a pragmatic, multicentre trial of the effectiveness and costs of atypical antipsychotic drugs in schizophrenia. Proceedings ot the 10th Biennial Winter Workshop on Schizophrenia; 2000 Feb 6-11; Davos, Switzerland</TI>
<SO>Schizophrenia Research</SO>
<YR>2000</YR>
<VL>41</VL>
<NO>1</NO>
<PG>214</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meltzer-2000" NAME="Meltzer 2000" YEAR="2000">
<REFERENCE PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>Suicide and schizophrenia: clozapine and the InterSePT study</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1999</YR>
<VL>60 Suppl 12</VL>
<PG>47-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2008-10-29 16:35:54 +0000" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2008-10-29 16:35:54 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Altman-1995" NAME="Altman 1995" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Absence of evidence is not evidence of absence</TI>
<SO>BMJ</SO>
<YR>1995</YR>
<VL>311</VL>
<PG>485</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Altman-1996" NAME="Altman 1996" TYPE="JOURNAL_ARTICLE">
<AU>Altman DG, Bland JM</AU>
<TI>Detecting skewness from summary information</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>1200</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE="NAVC020600"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Andreasen-1982" NAME="Andreasen 1982" TYPE="JOURNAL_ARTICLE">
<AU>Andreasen NC</AU>
<TI>Negative symptoms in schizophrenia: definition and reliability</TI>
<SO>Archieves of General Psychiatry</SO>
<YR>1982</YR>
<VL>39</VL>
<PG>784-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1994" NAME="APA 1994" TYPE="BOOK">
<AU>American Psychiatric Association</AU>
<SO>Diagnostic and Statistical Manual of Mental Disorders, 4th edition</SO>
<YR>1994</YR>
<PB>American Psychiatric Association</PB>
<CY>Washington, DC</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-APA-1997" NAME="APA 1997" TYPE="JOURNAL_ARTICLE">
<AU>American Psychiatric Association</AU>
<TI>Practice guideline for the treatment of patients with schizophrenia</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>154</VL>
<NO>4</NO>
<PG>1-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Benedetti-1999" NAME="Benedetti 1999" TYPE="JOURNAL_ARTICLE">
<AU>Benedetti F, Cavallaro R, Smeraldi E</AU>
<TI>Olanzapine-induced neutropenia after clozapine-induced neutropenia</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9178</NO>
<PG>567</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Birchwood-1990" NAME="Birchwood 1990" TYPE="JOURNAL_ARTICLE">
<AU>Birchwood M, Smith J, Cochrane R, Wetton S, Copestake S</AU>
<TI>The Social Functioning Scale. The development and validation of a new scale of social adjustment for use in family intervention programmes with schizophrenic patients</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1990</YR>
<VL>157</VL>
<PG>853-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Buckley-1997" NAME="Buckley 1997" TYPE="JOURNAL_ARTICLE">
<AU>Buckley PF</AU>
<TI>New dimensions in the pharmacologic treatment of schizophrenia and related psychoses</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1997</YR>
<VL>37</VL>
<PG>363-78</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carpenter-1994" NAME="Carpenter 1994" TYPE="JOURNAL_ARTICLE">
<AU>Carpenter WT Jr, Buchanan RW</AU>
<TI>Schizophrenia</TI>
<SO>New England Journal of Medicine</SO>
<YR>1994</YR>
<VL>330</VL>
<PG>681-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Casey-1997" NAME="Casey 1997" TYPE="JOURNAL_ARTICLE">
<AU>Casey DE</AU>
<TI>The relationship of pharmacology to side effects</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>10</NO>
<PG>55-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Claghorn-1987" NAME="Claghorn 1987" TYPE="JOURNAL_ARTICLE">
<AU>Claghorn J, Honigfeld G, Abuzzahab FS, Wang R, Steinbook R, Tuason V, et al</AU>
<TI>The risks and benefits of clozapine versus chlorpromazine</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1987</YR>
<VL>7</VL>
<PG>377-84</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-De-Prins-1997" NAME="De Prins 1997" TYPE="BOOK">
<AU>De Prins L (editor)</AU>
<SO>Psychotropics 1997/98</SO>
<YR>1997</YR>
<PB>Herrman &amp; Fischer A/S</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey-Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<PG>629-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-EMEA-1998" MODIFIED="2008-10-29 16:35:54 +0000" MODIFIED_BY="[Empty name]" NAME="EMEA 1998" TYPE="OTHER">
<AU>The European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit. Committee for the proprietary medicinal products (CPMP)</AU>
<TI>Note for guidance on the clinical investigation of medicinal products in the treatment of schizophrenia</TI>
<SO>http://www.eudra.org/emea.html</SO>
<YR>(accessed 26th february 1998)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erzigkeit-1986" NAME="Erzigkeit 1986" TYPE="BOOK">
<AU>Erzigkeit H</AU>
<SO>Manual zum Syndrom Kurztest (SKT)</SO>
<YR>1986</YR>
<PB>Vless</PB>
<CY>Vaterstetten</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Glazer-1997" NAME="Glazer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Glazer WM, Johnstone BM</AU>
<TI>Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1997</YR>
<VL>58</VL>
<NO>10</NO>
<PG>50-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guy-1976" MODIFIED="2008-10-29 16:17:35 +0000" MODIFIED_BY="[Empty name]" NAME="Guy 1976" TYPE="BOOK">
<AU>Guy W</AU>
<SO>Early Clinical Drug Evaluation Unit (ECDEU) assessment manual for psychopharmacology. Publication no 76-338</SO>
<YR>1976</YR>
<PB>National Institute of Mental Health</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hamilton-1960" NAME="Hamilton 1960" TYPE="JOURNAL_ARTICLE">
<AU>Hamilton M</AU>
<TI>A rating scale for depression</TI>
<SO>Journal of Neurology, Neurosurgery, and Psychiatry</SO>
<YR>1960</YR>
<VL>23</VL>
<PG>56-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hogan-1983" NAME="Hogan 1983" TYPE="JOURNAL_ARTICLE">
<AU>Hogan TP, Awad AG, Eastwood MR</AU>
<TI>A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity</TI>
<SO>Psychological Medicine</SO>
<YR>1983</YR>
<VL>13</VL>
<PG>177-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1996" NAME="Jones 1996" TYPE="JOURNAL_ARTICLE">
<AU>Jones B, Jarvis P, Lewis JA, Ebbutt AF</AU>
<TI>Trials to assess equivalence: the importance of rigorous methods</TI>
<SO>BMJ</SO>
<YR>1996</YR>
<VL>313</VL>
<PG>36-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1988" NAME="Kane 1988" TYPE="JOURNAL_ARTICLE">
<AU>Kane J, Honigfeld G, Singer J, Meltzer H</AU>
<TI>Clozapine for the treatment resistant schizophrenic: a double-blind comparison with chlorpromazine</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1988</YR>
<VL>45</VL>
<PG>789-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1996a" NAME="Kane 1996a" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Factors which can make patients difficult to treat</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1996</YR>
<VL>169</VL>
<NO>31</NO>
<PG>10-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kane-1996b" NAME="Kane 1996b" TYPE="JOURNAL_ARTICLE">
<AU>Kane JM</AU>
<TI>Treatment-resistant schizophrenic patients</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1996</YR>
<VL>57</VL>
<NO>9</NO>
<PG>35-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kay-1991" NAME="Kay 1991" TYPE="BOOK">
<AU>Kay SR</AU>
<SO>Positive and negative symptoms in schizophrenia. Assessment and research</SO>
<YR>1991</YR>
<PB>Brunner-Mazel</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerwin-1994" NAME="Kerwin 1994" TYPE="JOURNAL_ARTICLE">
<AU>Kerwin RW</AU>
<TI>The new atypical antipsychotics. A lack of extrapyramidal side-effects and new routes in schizophrenia research</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1994</YR>
<VL>164</VL>
<PG>141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kerwin-1996" NAME="Kerwin 1996" TYPE="JOURNAL_ARTICLE">
<AU>Kerwin R, Taylor D</AU>
<TI>New antipsychotics. A review of their current status and clinical potential</TI>
<SO>CNS Drugs</SO>
<YR>1996</YR>
<VL>6</VL>
<PG>71-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kilian-1999" NAME="Kilian 1999" TYPE="JOURNAL_ARTICLE">
<AU>Kilian JG, Kerr K, Lawrence C, Celermajer DS</AU>
<TI>Myocarditis and cardiomyopathy associated with clozapine</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<PG>1641-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lehrl-1980" NAME="Lehrl 1980" TYPE="BOOK">
<AU>Lehrl S, Gallwitz A, Blaha L</AU>
<SO>Manual zum Kurztest für die Allgemeine Intelligenz (KAI)</SO>
<YR>1980</YR>
<PB>Vless</PB>
<CY>Vaterstetten</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Meltzer-1996" NAME="Meltzer 1996" TYPE="JOURNAL_ARTICLE">
<AU>Meltzer HY</AU>
<TI>Cost-effectiveness of clozapine treatment</TI>
<SO>Journal of Clinical Psychiatry. Monograph Series</SO>
<YR>1996</YR>
<VL>14</VL>
<PG>16-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mulrow-1997" MODIFIED="2008-10-29 16:15:03 +0000" MODIFIED_BY="[Empty name]" NAME="Mulrow 1997" TYPE="OTHER">
<AU>Mulrow CD, Oxman AD, editors</AU>
<TI>Cochrane Collaboration Handbook [updated 1 September 1997]</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1997</YR>
<PB>Update Software; 1996-. Updated quarterly</PB>
<CY>Oxford</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Naumann-1999" NAME="Naumann 1999" TYPE="JOURNAL_ARTICLE">
<AU>Naumann R, Felber W, Heilemann H, Reuster T</AU>
<TI>Olanzapine-induced agranulocytosis</TI>
<SO>Lancet</SO>
<YR>1999</YR>
<VL>354</VL>
<NO>9178</NO>
<PG>566-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Overall-1962" NAME="Overall 1962" TYPE="JOURNAL_ARTICLE">
<AU>Overall JE, Gorham DR</AU>
<TI>The Brief Psychiatric Rating Scale</TI>
<SO>Psychological Reports</SO>
<YR>1962</YR>
<VL>10</VL>
<PG>799-812</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Robert-1997" NAME="Robert 1997" TYPE="JOURNAL_ARTICLE">
<AU>Robert G, Kennedy P</AU>
<TI>Establishing the cost effectiveness of atypical neuroleptics</TI>
<SO>British Journal of Psychiatry</SO>
<YR>1997</YR>
<VL>171</VL>
<PG>103-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schooler-1997" NAME="Schooler 1997" TYPE="JOURNAL_ARTICLE">
<AU>Schooler NR</AU>
<TI>New antipsychotic medications: strategies for evaluation and selected findings</TI>
<SO>Schizophrenia Research</SO>
<YR>1997</YR>
<VL>27</VL>
<PG>249-59</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Silverstone-1995" NAME="Silverstone 1995" TYPE="BOOK">
<AU>Silverstone T, Turner P</AU>
<SO>Drug treatment in psychiatry</SO>
<YR>1995</YR>
<EN>5th</EN>
<PB>TJ Press</PB>
<CY>Cornwall</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Simpson-1970" NAME="Simpson 1970" TYPE="JOURNAL_ARTICLE">
<AU>Simpson GM, Angus JWS</AU>
<TI>A rating scale for extrapyramidal side effects</TI>
<SO>Acta Psychiatrica Scandinavica</SO>
<YR>1970</YR>
<VL>46 Suppl 212</VL>
<PG>11-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Steinwachs-1999" NAME="Steinwachs 1999" TYPE="JOURNAL_ARTICLE">
<AU>Steinwachs A, Grohmann R, Pedrosa F, Rüther E, Schwerdtner I</AU>
<TI>Two cases of olazapine-induced reversible neutropenia</TI>
<SO>Pharmacopsychiatry</SO>
<YR>1999</YR>
<VL>32</VL>
<PG>154-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wahlbeck-1999" MODIFIED="2008-10-29 16:13:54 +0000" MODIFIED_BY="[Empty name]" NAME="Wahlbeck 1999" TYPE="COCHRANE_REVIEW">
<AU>Wahlbeck K, Cheine M, Essali MA</AU>
<TI>Clozapine versus typical neuroleptic medication for schizophrenia (</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-10-29 16:12:17 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-29 16:12:17 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000059"/>
</IDENTIFIERS>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2008-10-29 16:27:09 +0000" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Tuunainen-1999" MODIFIED="2008-10-29 16:27:09 +0000" MODIFIED_BY="[Empty name]" NAME="Tuunainen 1999" TYPE="COCHRANE_REVIEW">
<AU>Tuunainen A, Gilbody S</AU>
<TI>Newer atypical antipsychotic medication versus clozapine for schizophrenia</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>1999</YR>
<NO>1</NO>
<PB>Update Software</PB>
<CY>Oxford</CY>
<IDENTIFIERS MODIFIED="2008-10-29 16:27:09 +0000" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-10-29 16:27:09 +0000" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD000966"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Olanzapine-1998">
<CHAR_METHODS>
<P>Allocation:<BR/>"randomly allocated".<BR/>Blindness:<BR/>double - no further details.<BR/>Statistical technique: last observation carried forward.<BR/>Duration: 18 weeks (preceeded by 2-9 days washout).<BR/>Multicentre.<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N = 180.<BR/>Sex: 65 F, 115 M.<BR/>Age: mean 38.6 years (SD 10.6) range 18-70.<BR/>History: onset age ~ 23 years, duration ill ~ 16 years, treatment resistant.*<BR/>Setting: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Olanzapine: individual dose titration 15-25 mg/day, mean 22.2 mg/day. N = 90.<BR/>2. Clozapine: initial dose of 25-200 mg day 1-8, individual dose thereafter 200-600 mg/day, mean 354.2 mg/day. N = 90.<BR/>Benzodiazepine and chloral hydrate (agitation and insomnia), biperiden and benztropine mesylate (EPS) as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early. Physiological monitoring (vital signs, lab tests).<BR/>Mental state (PANSS, BPRS, CGI).<BR/>Adverse effects (dichotomous scale).</P>
<P>Unable to use:<BR/>Extrapyramidal symptoms (Barnes, modified SAS, AIMS) - mean endpoint values and SDs not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstracts only. Insufficient description of the dropouts - 107 patients completed the study: 60% in the olanzapine group, 58.9% in the clozapine group.<BR/>*Treatment resistant: lack of response to 2 antipsychotics of different class given at least 6 weeks at dose of at least 500 mg/day chlorpromazine equivalents or highest tolerated dose. BPRS(1-7) at least 45 and a score of at least 4 on at least 2 items on PANSS positive subscale (items 1-7).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Olanzapine-2000">
<CHAR_METHODS>
<P>Allocation: "randomly assigned".<BR/>Blindness: not stated.<BR/>Duration: 8 weeks.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia or other psychotic disorders (DSM-IV). <BR/>N = 36.<BR/>Sex: not stated.<BR/>Age: mean 34.1 years (olanzapine group mean 30 years, clozapine group mean 37 years).<BR/>History: treatment resistant.*</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Olanzapine: dose not stated. N = 21.<BR/>2. Clozapine: dose not stated. N = 15.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state (PANSS).</P>
<P>Unable to use:<BR/>Mental state (Calgary Depression Scale).<BR/>Cognitive and motor effects (a figure copying test, a simple motor aiming task, a key-pressing task, DST, Trail Making Test, a maze test).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Abstracts only. Missing description of the dropouts.<BR/>Additional information has been requested from the authors.<BR/>* Treatment resistant: no detailed description.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Remox_x002f_Risp_x002f_Zote-1996">
<CHAR_METHODS>
<P>Allocation: "randomly assigned".<BR/>Blindness: double - no further details.<BR/>Duration: 4 weeks (preceeded by neuroleptic free period).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (ICD-9) paranoid type.<BR/>N = 180.<BR/>Sex: 71 F, 64 M.*<BR/>Age: 34.7 years (SD 11). <BR/>History: acutly ill, duration ill ~ 4.5 years (SD 4.3).<BR/>Setting: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone: individual dose titration - first week, fixed dose thereafter 4 mg/day. N = 20.<BR/>2. Risperidone: individual dose titration - first week, fixed dose thereafter 8 mg/day. N = 20.<BR/>3. Zotepine: fixed dose 225 mg/day. N = 20.<BR/>4. Remoxipride: individual dose titration - first week, fixed dose thereafter 400 mg/day. N = 38.<BR/>5. Clozapine: initial dose of 100 mg/day, individual dose titration - first week, fixed dose thereafter 400 mg/day. N = 37.<BR/>6. Haloperidol: dose mean 15 mg/day. N = 45.<BR/>Biperiden (EPS) as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Physiological monitoring (physical investigation, lab tests, ECG, EEG).<BR/>Mental state (BPRS).<BR/>Cognitive changes (SKT).<BR/>Extrapyramidal side effects (SAS).<BR/>Satisfaction with treatment (dichotomous scale).</P>
<P>Unable to use:<BR/>Mental state (CGI) - not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No description whether there were dropouts or not. *Demographic data related to N = 135 (the haloperidol group excluded).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Remoxipride-1994">
<CHAR_METHODS>
<P>Allocation: "at random according to the study design".<BR/>Blindness: double - no further details.<BR/>Duration: 4 weeks, no neuroleptic pretreatment.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III), paranoid type.<BR/>N = 54.<BR/>Sex: 20 F, 14 M*. <BR/>Age: mean 31.9 years (SD 11).<BR/>History: acutely ill, duration ill ~ 5.5 years (SD 5.4). <BR/>Setting: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Remoxipride: mean dose 375 mg/day. N = 18.<BR/>2. Clozapine: mean dose 350 mg/day. N = 18.<BR/>3. Haloperidol: mean dose 16 mg/day. N = 18.<BR/>Biperiden (EPS), chloral durate (sleep disturbance) as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early, patient satisfaction.<BR/>Mental state (BPRS, CGI).<BR/>Cognitive changes (KAI, SKT).<BR/>Extrapyramidal symptoms (SAS).<BR/>Patient satisfaction (dichotomous scale).</P>
<P>Unable to use:<BR/>AMDB - mean endpoint values and SDs not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Description of the dropouts: "one patient in each group left the study prematurely". *Demographic data relates to remoxipride and clozapine group .</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Risperidone-1998a">
<CHAR_METHODS>
<P>Allocation: "randomly assigned", blocks of 4.<BR/>Blindness: double, "double-dummy" protocol.<BR/>Duration: 8 weeks (preceeded by neuroleptic free period).<BR/>Multicentre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-III-R).<BR/>N = 86.<BR/>Sex: 25 F, 61 M.<BR/>Age: mean 37.3 years (SD 12.6).<BR/>History: moderate-severe illness, duration ill ~ 14 years, onset age ~ 26 years (SD 8.8), treatment resistant.*<BR/>Setting: hospital (the first 3 weeks).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone: individual dose titration - first week, fixed dose thereafter 6 mg/day - second week, adjusted thereafter according to response, mean 6.4 mg/day, range 3-12 mg/day. N = 43.<BR/>2. Clozapine: individual dose titration - first week, fixed dose thereafter 300 mg/day - second week, adjusted thereafter according to response, mean 291 mg/day, range 150-400 mg/day. N = 43.<BR/>Lorazepam &amp; oxazepam (sleep induction), biperiden &amp; procyclidine (EPS), clothiapine (emergency treatment) as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early.<BR/>Mental state (PANSS, CGI).</P>
<P>Unable to use:<BR/>Extrapyramidal symptoms (ESRS) - endpoint mean values and SDs not reported. <BR/>Other adverse events (UKU) - mean endpoint data and SDs not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Description of the dropouts available - 34 patients completed the study in both groups. *Treatment resistant: failed to respond or intolerant of at least 2 different classes of antipsychotics in appropriate doses for at least 4 weeks each, total PANSS 60-120.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Risperidone-1998b">
<CHAR_METHODS>
<P>Allocation: "randomised".<BR/>Blindness: double - no further details.<BR/>Duration: 12 weeks.<BR/>Multicentre.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N = 273.<BR/>Sex: 78 F, 195 M.<BR/>Age: mean 38.8 years.<BR/>History: treatment resistant.*<BR/>Setting: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone: individual dose titration - week 1-4 up to 6 mg, then kept within a range of 2-15 mg, mean 8.3 mg/day. N = 135.<BR/>2. Clozapine: individual dose titration - week 1-4 up to 600 mg, then kept within a range of 200-900 mg, mean dose 597.5 mg/day. N = 138.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early, relapse.<BR/>Physiological monitoring (lab tests).</P>
<P>Unable to use:<BR/>Mental state (PANSS, BPRS, CGI, PAS) - data not reported.<BR/>Adverse effects - data not reported.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Raw scores of the rating scales not available.<BR/>Insufficient description of the dropouts - 101 patients in the risperidone group and 100 patients in the clozapine group completed the study. *Treatment resistant: severe, chronic disease and poor response to previous neuroleptics (no period of good functioning for at least 24 months despite the use of 2 antipsychotics, current episode without significant improvement for at least 6 months despite the use of an antipsychotic equivalent to haloperidol 20 mg for at least 6 weeks, total BPRS at least 45, and CGI at least 4.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Risperidone-1999">
<CHAR_METHODS>
<P>Allocation: "randomly assigned".<BR/>Blindness: double - no further details.<BR/>Duration: 6 weeks (preceeded by fluphenazine treatment for at least 2 weeks; then, 66% of the patients underwent a drug-free period, mean 18 days).<BR/>
</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N = 29.<BR/>Sex: 10 F, 19 M.<BR/>Age: mean 35.0 years, range 18-55 years.<BR/>History: duration ill ~12.5 years, chronic schizophrenia, partial response to neuroleptics.*<BR/>Setting: not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone: gradual dose titration up to 6 mg - 2 weeks, adjustments over the next 2 weeks within fixed limits 2-9 mg/day, thereafter fixed dose, mean 5.9 mg/day. N = 15.<BR/>2. Clozapine: gradual dose titration up to 400 mg/day - 2 weeks, adjustments over the next 2 weeks within fixed limits 200-600 mg/day, thereafter fixed dose, mean 403.6 mg/day. N = 14.<BR/>Bentztropine mesylate (EPS) as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early. Physiological monitoring (lab tests).<BR/>Mental state (BPRS, SANS, HDRS).<BR/>Extrapyramidal side effects (modified SAS).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No dropouts after randomisation phase. <BR/>*Partial response to neuroleptics: 1) a history of residual positive and/or negative symptoms after at least a 6-week trial of a therapeutic dose of a neuroleptic agent, 2) at least a minimum level of positive (4 positive BPRS items at least 8) and/or negative (SANS score at least 20) symptoms at the time of evaluation for the study, and 3) at least a minimum level of positive and negative symptoms after a prospective trial of of a least 2 weeks of fluphenazine 20 mg/day (range 10-30 mg/day).</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Risperidone-2000">
<CHAR_METHODS>
<P>Allocation: "computer-generated randomisation".<BR/>Blindness: single - a blind rater.<BR/>Statistical technique: last observation carried forward.<BR/>Duration: 10 weeks (preceeded by 6-week treatment of haloperidol up to 50 mg/day if no history of previous haloperidol treatment higher than 40 mg/day or haloperidol intolerance).<BR/>Washout of previous neuroleptic medication 1-3 days.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N = 20.<BR/>Sex: 9 F, 11 M.<BR/>Age: mean 35.9 years, range 24-55 years.<BR/>History: duration ill ~12 years, range 0.5-33 years, treatment resistant.*<BR/>Setting:hospital (at the beginning of the trial).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Risperidone: fixed dose titration up to 6 mg - 3 days, flexible daily dose thereafter up to 10 mg/day, mean 7.8 mg/day. N = 9.<BR/>2. Clozapine: fixed dose titration up to 400 mg - 2 weeks, flexible daily dose thereafter up to 600 mg/day, mean 385 mg/day. N = 11.<BR/>Biperiden (EPS) and lorazepam (anxiety) as required.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Leaving the study early, relapse, discharge rate. Physiological monitoring (lab tests).<BR/>Mental state (PANSS, CGI, PGI, SFS).<BR/>Extrapyramidal symptoms (non-structured assessment).<BR/>Global assessment (GAF).<BR/>Satisfaction with treatment (DAI-10).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Description of dropouts available - 8 patients in the risperidone group and 5 patients in the clozapine group completed the study (one of the subjects randomised to clozapine withdrew his consent before the beginning of the trial). <BR/>*Treatment resistance: persistent psychotic symptoms for at least 6 months while on medication of at least 2 different classes of antipsychotics in doses equivalent or greater than 1000 mg/day chlorpromazine for at least 6 weeks each. In addition, non-tolerance to haloperidol or non-response to more than 40 mg/day dose of haloperidol treatment.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>General Abbreviations:<BR/>ECG = Electrocardiogram<BR/>EEG = Electroencephalogram<BR/>EPS = Extrapyramidal side effects<BR/>F = female<BR/>lab = laboratory<BR/>M = male<BR/>mg = milligram<BR/>N = number of patients<BR/>SD = standard deviation</P>
<P>Diagnostic Tools:<BR/>DSM-III = Diagnostic and Statistical Manual of Mental Disorders, third edition<BR/>DSM-III-R = Diagnostic and Statistical Manual of Mental Disorders, third edition, revised<BR/>DSM-IV = Diagnostic and Statistical Manual of Mental Disorders, fourth edition<BR/>ICD-9 = International Classification of Diseases, ninth revision</P>
<P>Rating Scales:</P>
<P>Adverse effect scales<BR/>AIMS = Abnormal Involuntary Movement Scale<BR/>Barnes = Barnes Akathisia Scale<BR/>ESRS = Extrapyramidal Symptom Rating Scale<BR/>SAS = Simpson and Angus Scale (Simpson-Angus Index) (Simpson 1970)<BR/>UKU = Udvalg for Kliniske Undersogelser</P>
<P>Cognitive scales<BR/>DST = Digit Symbol Test<BR/>KAI = Short Test for General Intelligence (Lehrl 1980)<BR/>MMSE = Mini Mental State Exam<BR/>SKT = Syndrome short Test (Erzigkeit 1986)<BR/>WAIS = Wechsler Adult Intelligence Scale<BR/>WMS = Wechsler Memory Scale</P>
<P>General symptom scales<BR/>AMDP = Association for Methodology and Documentation in Psychiatry for Somatic Findings<BR/>NOSIE = Nurses' Observation Scale for Inpatient Evaluation </P>
<P>Global assessment scales<BR/>CGI = Clinical Global Impressions (Guy 1976)<BR/>GAF = Global Assessment of Functioning (APA 1994)<BR/>PGI = Patient Global Impression (Guy 1976)</P>
<P>Mental state scales<BR/>BPRS = Brief Psychiatric Rating Scale (Overall 1962)<BR/>HDRS = Hamilton Depression Rating Scale (Hamilton 1960)<BR/>PANSS = Positive and Negative Syndrome Scale (Kay 1991)<BR/>PAS = Psychotic Anxiety Scale<BR/>SANS = Scale for the Assessment of Negative Symptoms (Andreasen 1982)</P>
<P>Social functioning scales<BR/>SFS = Social Functioning Scale (Birchwood 1990)</P>
<P>Treatment satisfaction scales<BR/>DAI-10 = Drug Attitude Inventory (Hogan 1983)</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Busatto-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, historical controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Cavallaro-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, open study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chouinard-1994">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, open study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Eikelmann-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Flynn-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, open clinical trial. <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Gallhofer-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Honer-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Klemm-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Konrad-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Konrad-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, open study.<BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kufferle-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Kumra-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, open study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindenmayer-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, open study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Meyer_x002d_Lindenberg1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, originally randomised but this phase of study aborted. <BR/>
</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Naber-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised, ongoing study.<BR/>Participants: those with schizophnrenia.<BR/>Interventions: olanzapine versus risperidone versus zotepine - clozapine not included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Nicolini-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: randomised.<BR/>Participants: those with schizophrenia.<BR/>Interventions: olanzapine versus risperidone - clozapine not included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pilowsky-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Pilowsky-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, historical controls.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Rapoport-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Robinson-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Sharif-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised, retrospective study.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Su-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tauscher-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Thompson-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Tran-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: unclear, double-blind prospective study. <BR/>Participants: those with schizophrenia, schizophreniform disorder, schizoaffective disorder.<BR/>Intervention: olanzapine versus risperidone - clozapine not included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Travis-1997">
<CHAR_REASON_FOR_EXCLUSION>
<P>Allocation: not randomised.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<AWAITING_CHAR STUDY_ID="STD-Daniel-1996">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Estrella-1996">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<AWAITING_CHAR STUDY_ID="STD-Su-1997">
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_NOTES/>
</AWAITING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Lewis-2000">
<CHAR_STUDY_NAME>
<P>The CutLASS Study.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenia (DSM-IV).<BR/>N = 702.<BR/>Age: 18-65 years.<BR/>History: treatment resistant or -intolerant, with unsatisfactory response to two previous antipsychotic drugs.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. New atypical drugs. <BR/>2. Clozapine.<BR/>3. Conventional antipsychotic drugs.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mental state (PANSS, Calgary Depression Scale).<BR/>Adverse effects (AIMS, Barnes, SAS).<BR/>Global assessment (GAF, QLS).<BR/>Treatment satisfaction (DAI).<BR/>Cost effectiveness (EQ-5D).</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Currently ongoing study.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Prof. S.W. Lewis<BR/>School of Psychiatry and Behavioural Sciences<BR/>University of Manchester <BR/>M20 8LR Manchester<BR/>UK</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Allocation:<BR/>randomised.<BR/>Blindness:<BR/>single.<BR/>Randomisation between classes of drugs rather than individual drugs.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Meltzer-2000">
<CHAR_STUDY_NAME>
<P>The International Clozaril/Leponex Suicide Prevention Trial (InterSePT).</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>Diagnosis: schizophrenic patients. <BR/>Multicentre (11 countries, 69 centres). <BR/>N= 20 to 40 patients at each of the centres in Europe and in the Southern Hemisphere, at least 40 patients at each centre in the US. <BR/>History: treatment resistant.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>1. Olanzapine (10-20 mg/day).<BR/>2. Clozapine (300-900 mg/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Rate of hospitalization for imminent risk of suicide and suicide attempts in schizophrenic patients at high risk of suicide randomly assigned to receive olanzapine and clozapine.<BR/>The effect of treatment on the severity of suicide attempt (CGI-SS).<BR/>Suicide-, psychotic-, and mood-related events and pharmacolocic aspects.</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Currently ongoing study.<BR/>Results available in 2001.</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Prof. H. Y. Meltzer<BR/>Department of Psychiatry<BR/>Vanderbilt University<BR/>1601 23rd Ave.S.<BR/>Suite 306<BR/>Nashville, TN 37212<BR/>USA</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Allocation:<BR/>randomised.<BR/>Blindness: <BR/>not stated.</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>Rating scales</P>
<P>Adverse effect scales<BR/>AIMS = Abnormal Involuntary Movement Scale<BR/>Barnes = Barnes Akathisia Scale<BR/>SAS = Simpson-Angus Scale </P>
<P>Global assessment scales<BR/>CGI-SS = Clinical Global Impressions-Severity of Suicide scale<BR/>GAF = Global Assessment of Functioning<BR/>QLS = Quality of Life Scale</P>
<P>Mental state scales<BR/>PANSS = Positive and Negative Syndrome Scale</P>
<P>Treatment satisfaction scales<BR/>DAI = Drug Attitude Inventory</P>
<P>Cost effectiveness scales<BR/>EQ-5D = Cost-utility ratio</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Olanzapine-1998">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Olanzapine-2000">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Remox_x002f_Risp_x002f_Zote-1996">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Remoxipride-1994">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Risperidone-1998a">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Risperidone-1998b">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Risperidone-1999">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Risperidone-2000">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>NEWER ATYPICAL ANTIPSYCHOTIC DRUGS versus CLOZAPINE</NAME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="1" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="228" WEIGHT="0.0" Z="0.0">
<NAME>Death</NAME>
<GROUP_LABEL_1>new atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.01" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="1" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="114" TOTAL_2="114" WEIGHT="0.0" Z="0.0">
<NAME>all deaths</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30554" O_E="0.0" SE="0.0" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30555" O_E="0.0" SE="0.0" STUDY_ID="STD-Risperidone-1999" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30556" O_E="0.0" SE="0.0" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.0" CI_START="0.0" DF="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" ID="CMP-001.01.02" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" NO="2" P_CHI2="0.0" P_Z="0.0" STUDIES="3" TAU2="0.0" TOTAL_1="114" TOTAL_2="114" WEIGHT="0.0" Z="0.0">
<NAME>suicides</NAME>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30557" O_E="0.0" SE="0.0" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30558" O_E="0.0" SE="0.0" STUDY_ID="STD-Risperidone-1999" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30559" O_E="0.0" SE="0.0" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.1260314025044877" CI_START="0.4697254611712329" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="33" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.05155050218872832" LOG_CI_START="-0.32815589852129123" LOG_EFFECT_SIZE="-0.13830269816628143" METHOD="MH" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.1533556386200875" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0" Z="1.4277784459980136">
<NAME>Global impression: 1. Clinically not improved (CGI) - medium term</NAME>
<GROUP_LABEL_1>new atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1260314025044877" CI_START="0.4697254611712329" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="33" LOG_CI_END="0.05155050218872832" LOG_CI_START="-0.32815589852129123" LOG_EFFECT_SIZE="-0.13830269816628143" ORDER="30560" O_E="0.0" SE="0.22304141935406244" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.049747474747474735" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4751911009406756E-32" CI_END="1.9493210811065758" CI_START="0.12261312309993157" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.4888888888888888" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="100.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="0.2898833795321965" LOG_CI_START="-0.9114630454384716" LOG_EFFECT_SIZE="-0.3107898329531375" METHOD="MH" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.31053967915809966" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="11" WEIGHT="100.0" Z="1.014090301828204">
<NAME>Global impression: 2. Not ready for discharge - short term</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.949321081106576" CI_START="0.12261312309993162" EFFECT_SIZE="0.4888888888888889" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" LOG_CI_END="0.28988337953219656" LOG_CI_START="-0.9114630454384713" LOG_EFFECT_SIZE="-0.31078983295313745" ORDER="30561" O_E="0.0" SE="0.705676836788482" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.49797979797979786" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.8412318208857315" CI_END="0.15227961234672616" CI_START="-0.3433724688409597" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.09554642824711676" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="0.41675743808211485" P_Q="0.9690154911678344" P_Z="0.4498643736617087" Q="0.0015087859741242937" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="158" TOTAL_2="157" UNITS="" WEIGHT="100.0" Z="0.7556411657429429">
<NAME>Global impression: 3. CGI endpoint score (high = poor)</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.839723034911607" CI_END="0.23113063573464565" CI_START="-0.4309219433941537" DF="2.0" EFFECT_SIZE="-0.09989565382975402" ESTIMABLE="YES" I2="29.57059630773976" ID="CMP-001.04.01" NO="1" P_CHI2="0.24174781674430756" P_Z="0.554206030431285" STUDIES="3" TAU2="0.0" TOTAL_1="69" TOTAL_2="70" WEIGHT="56.049133716055664" Z="0.591469287759721">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.2705834703904505" CI_START="-0.6705834703904509" EFFECT_SIZE="-0.20000000000000018" ESTIMABLE="YES" MEAN_1="1.9" MEAN_2="2.1" ORDER="30562" SD_1="0.7" SD_2="0.7" SE="0.24009801919951235" STUDY_ID="STD-Remoxipride-1994" TOTAL_1="17" TOTAL_2="17" WEIGHT="27.734512751486854"/>
<CONT_DATA CI_END="0.7287934073396481" CI_START="-0.3287934073396478" EFFECT_SIZE="0.20000000000000018" ESTIMABLE="YES" MEAN_1="3.1" MEAN_2="2.9" ORDER="30563" SD_1="1.3" SD_2="1.2" SE="0.2697975123577284" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" WEIGHT="21.96452485148761"/>
<CONT_DATA CI_END="0.2834602001602352" CI_START="-1.6834602001602357" EFFECT_SIZE="-0.7000000000000002" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="4.4" ORDER="30564" SD_1="1.3" SD_2="0.8" SE="0.5017746284715657" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="6.350096113081199"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.28382059002620474" CI_START="-0.46382059002620446" DF="0.0" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" NO="2" P_CHI2="1.0" P_Z="0.6370156948326527" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="87" WEIGHT="43.950866283944336" Z="0.4718754485841438">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.28382059002620474" CI_START="-0.46382059002620446" EFFECT_SIZE="-0.08999999999999986" ESTIMABLE="YES" MEAN_1="4.44" MEAN_2="4.53" ORDER="30565" SD_1="1.26" SD_2="1.27" SE="0.19072829550688364" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="89" TOTAL_2="87" WEIGHT="43.950866283944336"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="0.44269704670700705" CI_START="-18.442697046707007" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.06175147633737428" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="1.8680760140464372">
<NAME>Global impression: 4. GAF endpoint score (high = good) - short term</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.44269704670700705" CI_START="-18.442697046707007" EFFECT_SIZE="-9.0" ESTIMABLE="YES" MEAN_1="-44.0" MEAN_2="-35.0" ORDER="30566" SD_1="10.0" SD_2="11.0" SE="4.817791102892602" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="2.703271541340525" CI_END="1.156950297693361" CI_START="0.7459613362664606" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9289995640802093" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="83" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.06331470216596119" LOG_CI_START="-0.1272836817515605" LOG_EFFECT_SIZE="-0.03198448979279963" METHOD="MH" NO="6" P_CHI2="0.6086424570091016" P_Q="0.0" P_Z="0.5106623454245657" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="178" TOTAL_2="173" WEIGHT="100.0" Z="0.6578067113612429">
<NAME>Mental state: 1. Clinically not improved (&lt; 20% change on BPRS/PANSS)</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="1.8042586250018" CI_END="1.340691078351744" CI_START="0.7462155411337055" DF="3.0" EFFECT_SIZE="1.0002222345685872" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="40" I2="0.0" ID="CMP-001.06.01" LOG_CI_END="0.12732871937069892" LOG_CI_START="-0.12713571032289478" LOG_EFFECT_SIZE="9.65045239020755E-5" NO="1" P_CHI2="0.6140087971014856" P_Z="0.9988138528281549" STUDIES="4" TAU2="0.0" TOTAL_1="88" TOTAL_2="83" WEIGHT="49.038251961639055" Z="0.001486615566828">
<NAME>short term</NAME>
<DICH_DATA CI_END="1.6779412285382824" CI_START="0.6841474326687232" EFFECT_SIZE="1.0714285714285714" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="10" LOG_CI_END="0.22477674518844115" LOG_CI_START="-0.16485029843355475" LOG_EFFECT_SIZE="0.029963223377443202" ORDER="30567" O_E="0.0" SE="0.22886885410853178" STUDY_ID="STD-Olanzapine-2000" TOTAL_1="21" TOTAL_2="15" VAR="0.0523809523809524" WEIGHT="13.826830863121184"/>
<DICH_DATA CI_END="1.6890171601512383" CI_START="0.5157503024025581" EFFECT_SIZE="0.9333333333333333" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.22763406195770663" LOG_CI_START="-0.28756050871259303" LOG_EFFECT_SIZE="-0.02996322337744321" ORDER="30568" O_E="0.0" SE="0.3026278410659888" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.09158361018826136" WEIGHT="17.777353966870095"/>
<DICH_DATA CI_END="1.9816804798978511" CI_START="0.7814791491454108" EFFECT_SIZE="1.2444444444444445" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.2970336314793739" LOG_CI_START="-0.10708260501766043" LOG_EFFECT_SIZE="0.09497551323085675" ORDER="30569" O_E="0.0" SE="0.2373798777259908" STUDY_ID="STD-Risperidone-1999" TOTAL_1="15" TOTAL_2="14" VAR="0.05634920634920634" WEIGHT="11.034219703574541"/>
<DICH_DATA CI_END="1.7814352539781018" CI_START="0.20963814951427226" EFFECT_SIZE="0.6111111111111112" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="6" LOG_CI_END="0.2507700426000194" LOG_CI_START="-0.6785296824901814" LOG_EFFECT_SIZE="-0.21387981994508098" ORDER="30570" O_E="0.0" SE="0.5458752586258128" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.297979797979798" WEIGHT="6.399847428073235"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.1948699170018031" CI_START="0.6196492235665146" DF="0.0" EFFECT_SIZE="0.8604651162790697" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="43" I2="0.0" ID="CMP-001.06.02" LOG_CI_END="0.0773206271223116" LOG_CI_START="-0.20785409014749462" LOG_EFFECT_SIZE="-0.06526673151259155" NO="2" P_CHI2="1.0" P_Z="0.36964564774394226" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="50.96174803836094" Z="0.8971373365633829">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.1948699170018031" CI_START="0.6196492235665146" EFFECT_SIZE="0.8604651162790697" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="43" LOG_CI_END="0.0773206271223116" LOG_CI_START="-0.20785409014749462" LOG_EFFECT_SIZE="-0.06526673151259155" ORDER="30571" O_E="0.0" SE="0.16751304056190125" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.028060618758293174" WEIGHT="50.96174803836094"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.599689428209865" CI_END="1.3827308338013955" CI_START="0.7890948011999253" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.0445600568715612" ESTIMABLE="YES" EVENTS_1="76" EVENTS_2="73" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="0.1407376473748093" LOG_CI_START="-0.10287081787455567" LOG_EFFECT_SIZE="0.018933414750126817" METHOD="MH" NO="7" P_CHI2="0.46665718858518945" P_Q="0.0" P_Z="0.76062553376426" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="316" TOTAL_2="315" WEIGHT="100.0" Z="0.3046594540680045">
<NAME>Mental state: 2. Deterioration in mental state or relapse</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="3.699430540583033" CI_END="1.3398187399471522" CI_START="0.66769131447328" DF="4.0" EFFECT_SIZE="0.9458252141020812" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="51" I2="0.0" ID="CMP-001.07.01" LOG_CI_END="0.12704604794285715" LOG_CI_START="-0.17542427316124698" LOG_EFFECT_SIZE="-0.024189112609194915" NO="1" P_CHI2="0.44820884031263986" P_Z="0.7539130431666117" STUDIES="5" TAU2="0.0" TOTAL_1="226" TOTAL_2="225" WEIGHT="69.79681217526864" Z="0.31348391048051455">
<NAME>short term</NAME>
<DICH_DATA CI_END="27.527937326919155" CI_START="0.46335117264101394" EFFECT_SIZE="3.5714285714285716" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.4397736708521878" LOG_CI_START="-0.33408973353662624" LOG_EFFECT_SIZE="0.5528419686577808" ORDER="30572" O_E="0.0" SE="1.0419761445034554" STUDY_ID="STD-Olanzapine-2000" TOTAL_1="21" TOTAL_2="15" VAR="1.0857142857142856" WEIGHT="1.601684202826663"/>
<DICH_DATA CI_END="14.786473993825217" CI_START="0.06762937536140103" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.169864623787869" LOG_CI_START="-1.169864623787869" LOG_EFFECT_SIZE="0.0" ORDER="30573" O_E="0.0" SE="1.3743685418725535" STUDY_ID="STD-Remoxipride-1994" TOTAL_1="18" TOTAL_2="18" VAR="1.8888888888888888" WEIGHT="1.3728721738514253"/>
<DICH_DATA CI_END="2.8738222164099336" CI_START="0.4544896484971988" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.45845989782036123" LOG_CI_START="-0.3424760038649878" LOG_EFFECT_SIZE="0.05799194697768673" ORDER="30574" O_E="0.0" SE="0.47047371334662913" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.22134551495016613" WEIGHT="9.610105216959978"/>
<DICH_DATA CI_END="1.360663708067324" CI_START="0.6147952102301713" EFFECT_SIZE="0.9146198830409357" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.13375080134037534" LOG_CI_START="-0.21126952467702462" LOG_EFFECT_SIZE="-0.038759361668324645" ORDER="30575" O_E="0.0" SE="0.20266664738077883" STUDY_ID="STD-Risperidone-1998b" TOTAL_1="135" TOTAL_2="138" VAR="0.04107376996056495" WEIGHT="51.595855324965655"/>
<DICH_DATA CI_END="2.1896090645185575" CI_START="0.008119156093138794" EFFECT_SIZE="0.13333333333333333" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="4" LOG_CI_END="0.3403665822931168" LOG_CI_START="-2.090489109076517" LOG_EFFECT_SIZE="-0.8750612633917001" ORDER="30576" O_E="0.0" SE="1.4278966660402597" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="11" VAR="2.0388888888888888" WEIGHT="5.616295256664921"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="2.0483205190532807" CI_START="0.790811152686435" DF="0.0" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" I2="0.0" ID="CMP-001.07.02" LOG_CI_END="0.3113979155678108" LOG_CI_START="-0.10192721452778485" LOG_EFFECT_SIZE="0.10473535052001297" NO="2" P_CHI2="1.0" P_Z="0.32056475944414997" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="30.20318782473136" Z="0.993298011567438">
<NAME>medium term</NAME>
<DICH_DATA CI_END="2.0483205190532807" CI_START="0.790811152686435" EFFECT_SIZE="1.2727272727272727" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="22" LOG_CI_END="0.3113979155678108" LOG_CI_START="-0.10192721452778485" LOG_EFFECT_SIZE="0.10473535052001297" ORDER="30577" O_E="0.0" SE="0.24278922741054418" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.05894660894660894" WEIGHT="30.20318782473136"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="3.0240265635434773" CI_END="0.08906641998063344" CI_START="-0.35824883107638084" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.13459120554787368" ESTIMABLE="YES" I2="0.7945222384331043" I2_Q="0.0" ID="CMP-001.08" NO="8" P_CHI2="0.3879357794821833" P_Q="0.7323365239518419" P_Z="0.23821740295446536" Q="0.11697710656460059" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="156" TOTAL_2="154" UNITS="" WEIGHT="99.99999999999999" Z="1.1794541540281045">
<NAME>Mental state: 3. Negative symptoms endpoint score (PANSS/SANS, high = poor)</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="2.9070494569788767" CI_END="0.16220371219648913" CI_START="-0.5216508073455661" DF="2.0" EFFECT_SIZE="-0.17972354757453848" ESTIMABLE="YES" I2="31.201720865166124" ID="CMP-001.08.01" NO="1" P_CHI2="0.23374499573111263" P_Z="0.30291859107317387" STUDIES="3" TAU2="0.0" TOTAL_1="67" TOTAL_2="67" WEIGHT="42.78583067512458" Z="1.0301947866214372">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.3805833436427437" CI_START="-0.4649084953426983" EFFECT_SIZE="-0.042162575849977305" ESTIMABLE="YES" MEAN_1="21.2" MEAN_2="21.5" ORDER="30578" SD_1="6.9" SD_2="7.2" SE="0.21569065698517262" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" WEIGHT="27.99036560231133"/>
<CONT_DATA CI_END="0.5851166608690214" CI_START="-0.8737646165445511" EFFECT_SIZE="-0.14432397783776485" ESTIMABLE="YES" MEAN_1="47.6" MEAN_2="48.93" ORDER="30579" SD_1="9.42" SD_2="8.43" SE="0.3721704298959169" STUDY_ID="STD-Risperidone-1999" TOTAL_1="15" TOTAL_2="14" WEIGHT="9.401291298801366"/>
<CONT_DATA CI_END="0.007764935304141796" CI_START="-1.9182126964981716" EFFECT_SIZE="-0.9552238805970149" ESTIMABLE="YES" MEAN_1="17.0" MEAN_2="21.0" ORDER="30580" SD_1="4.0" SD_2="4.0" SE="0.4913298527407083" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="5.39417377401188"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="8.461996567850809E-33" CI_END="0.19484639010219168" CI_START="-0.39652717470538695" DF="0.0" EFFECT_SIZE="-0.10084039230159762" ESTIMABLE="YES" I2="99.99999999999999" ID="CMP-001.08.02" NO="2" P_CHI2="0.0" P_Z="0.5038642893113671" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="87" WEIGHT="57.21416932487541" Z="0.6684219547836259">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.19484639010219168" CI_START="-0.39652717470538695" EFFECT_SIZE="-0.10084039230159764" ESTIMABLE="YES" MEAN_1="22.01" MEAN_2="22.76" ORDER="30581" SD_1="7.61" SD_2="7.19" SE="0.15086337541716527" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="89" TOTAL_2="87" WEIGHT="57.21416932487541"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="1.9881203718724576" CI_END="0.5216372864102713" CI_START="-0.16034246303965996" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.18064741168530565" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.09" NO="9" P_CHI2="0.3700711847122836" P_Q="1.0" P_Z="0.29911317995298703" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="67" TOTAL_2="67" UNITS="" WEIGHT="99.99999999999999" Z="1.038337050591774">
<NAME>Mental state: 4. Positive symptoms endpoint score (BPRS/PANSS, high = poor) - short term</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.5891921723744131" CI_START="-0.2577208985190119" EFFECT_SIZE="0.1657356369277006" ESTIMABLE="YES" MEAN_1="18.7" MEAN_2="17.4" ORDER="30582" SD_1="8.13" SD_2="7.4" SE="0.21605322280760444" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" WEIGHT="64.84332656616043"/>
<CONT_DATA CI_END="1.2903338041898071" CI_START="-0.19744768112608946" EFFECT_SIZE="0.5464430615318588" ESTIMABLE="YES" MEAN_1="9.53" MEAN_2="7.43" ORDER="30583" SD_1="4.73" SD_2="2.21" SE="0.3795430673857599" STUDY_ID="STD-Risperidone-1999" TOTAL_1="15" TOTAL_2="14" WEIGHT="21.011867734877484"/>
<CONT_DATA CI_END="0.6122804543670042" CI_START="-1.2010334259652493" EFFECT_SIZE="-0.2943764857991226" ESTIMABLE="YES" MEAN_1="15.0" MEAN_2="17.0" ORDER="30584" SD_1="7.0" SD_2="6.0" SE="0.4625885716868886" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="14.144805698962076"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="7.448872901970856" CI_END="0.256494694382278" CI_START="-0.11445397801880106" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="SMD" EFFECT_SIZE="0.07102035818173849" ESTIMABLE="YES" I2="32.87575092498789" I2_Q="0.0" ID="CMP-001.10" NO="10" P_CHI2="0.18933949322172972" P_Q="0.5512820008847278" P_Z="0.4529573468506266" Q="0.35502591242451054" RANDOM="NO" SCALE="1.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="271" TOTAL_2="208" UNITS="" WEIGHT="100.0" Z="0.7504938260290541">
<NAME>Mental state: 5. Psychosis symptoms rating scale endpoint score (BPRS/PANSS, high = poor)</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="7.093846989546345" CI_END="0.35473593622025784" CI_START="-0.12177001970918076" DF="4.0" EFFECT_SIZE="0.11648295825553855" ESTIMABLE="YES" I2="43.61310575355669" ID="CMP-001.10.01" NO="1" P_CHI2="0.13101140000071332" P_Z="0.3379441555744217" STUDIES="5" TAU2="0.0" TOTAL_1="182" TOTAL_2="121" WEIGHT="60.60256074662108" Z="0.9582352545761058">
<NAME>short term</NAME>
<CONT_DATA CI_END="0.3781821925539984" CI_START="-0.3781821925539984" EFFECT_SIZE="0.0" ESTIMABLE="YES" MEAN_1="38.4" MEAN_2="38.4" ORDER="30585" SD_1="18.0" SD_2="17.8" SE="0.19295364381032062" STUDY_ID="STD-Remox_x002f_Risp_x002f_Zote-1996" TOTAL_1="98" TOTAL_2="37" WEIGHT="24.05279224627066"/>
<CONT_DATA CI_END="1.4834728539407624" CI_START="0.08192983640392304" EFFECT_SIZE="0.7827013451723428" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="36.0" ORDER="30586" SD_1="21.0" SD_2="13.0" SE="0.35754305400304087" STUDY_ID="STD-Remoxipride-1994" TOTAL_1="17" TOTAL_2="17" WEIGHT="7.005107075789772"/>
<CONT_DATA CI_END="0.49046542177861363" CI_START="-0.3551813083939591" EFFECT_SIZE="0.06764205669232728" ESTIMABLE="YES" MEAN_1="78.9" MEAN_2="77.2" ORDER="30587" SD_1="25.5" SD_2="24.3" SE="0.21573017076918918" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" WEIGHT="19.241977139320614"/>
<CONT_DATA CI_END="1.1791441509072524" CI_START="-0.2978389054659729" EFFECT_SIZE="0.44065262272063976" ESTIMABLE="YES" MEAN_1="35.8" MEAN_2="32.0" ORDER="30588" SD_1="9.89" SD_2="6.37" SE="0.37678831550566216" STUDY_ID="STD-Risperidone-1999" TOTAL_1="15" TOTAL_2="14" WEIGHT="6.307781133114254"/>
<CONT_DATA CI_END="0.30095203879929433" CI_START="-1.5549741217735027" EFFECT_SIZE="-0.6270110414871042" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="76.0" ORDER="30589" SD_1="17.0" SD_2="22.0" SE="0.47345925109137355" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="3.9949031521257865"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.2965829385853971" CI_START="-0.29440664157935403" DF="0.0" EFFECT_SIZE="0.001088148503021524" ESTIMABLE="YES" I2="0.0" ID="CMP-001.10.02" NO="2" P_CHI2="1.0" P_Z="0.9942413229626759" STUDIES="1" TAU2="0.0" TOTAL_1="89" TOTAL_2="87" WEIGHT="39.39743925337891" Z="0.007217494004408052">
<NAME>medium term</NAME>
<CONT_DATA CI_END="0.2965829385853971" CI_START="-0.29440664157935403" EFFECT_SIZE="0.001088148503021524" ESTIMABLE="YES" MEAN_1="82.6" MEAN_2="82.57" ORDER="30590" SD_1="29.06" SD_2="25.7" SE="0.15076541835115376" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="89" TOTAL_2="87" WEIGHT="39.39743925337891"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.11" NO="11" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Mental state: 6. Depression (HDRS, high = poor, data skewed) - short term</NAME>
<TR>
<TH>
<P>New atypical</P>
</TH>
<TH>
<P>Clozapine</P>
</TH>
<TH>
<P>Notes</P>
</TH>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="38" STUDY_ID="STD-Risperidone-1999">
<TR>
<TD>
<P>Baseline: mean 11.77, SD 8.83.<BR/>Endpoint: mean 9.85, SD 5.91.</P>
</TD>
<TD>
<P>Baseline: mean 12.86, SD 5.42.<BR/>Endpoint: mean 8.36, SD 3.61.</P>
</TD>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<DICH_OUTCOME CHI2="2.5295655775420727" CI_END="1.161429485311724" CI_START="0.7058719631357975" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9054394020809926" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="91" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="0.06499284730918141" LOG_CI_START="-0.15127406771081445" LOG_EFFECT_SIZE="-0.04314061020081654" METHOD="MH" NO="12" P_CHI2="0.6393496636654481" P_Q="0.0" P_Z="0.43424893771884443" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="310" TOTAL_2="314" WEIGHT="100.0" Z="0.7819415397576084">
<NAME>Acceptability of treatment: 1. Leaving the study early</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="2.3881184984178385" CI_END="1.2126119738412655" CI_START="0.6074825167618858" DF="3.0" EFFECT_SIZE="0.8582776786825403" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="54" I2="0.0" ID="CMP-001.12.01" LOG_CI_END="0.083721852326718" LOG_CI_START="-0.21646621646726094" LOG_EFFECT_SIZE="-0.06637218207027147" NO="1" P_CHI2="0.49585037545262756" P_Z="0.3861042717529136" STUDIES="5" TAU2="0.0" TOTAL_1="220" TOTAL_2="224" WEIGHT="58.88085584485369" Z="0.8667039096903405">
<NAME>short term</NAME>
<DICH_DATA CI_END="14.786473993825217" CI_START="0.06762937536140103" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.169864623787869" LOG_CI_START="-1.169864623787869" LOG_EFFECT_SIZE="0.0" ORDER="30592" O_E="0.0" SE="1.3743685418725535" STUDY_ID="STD-Remoxipride-1994" TOTAL_1="18" TOTAL_2="18" VAR="1.8888888888888888" WEIGHT="1.1113282204093595"/>
<DICH_DATA CI_END="2.274078044403178" CI_START="0.4397386459365979" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.35680536522068085" LOG_CI_START="-0.35680536522068085" LOG_EFFECT_SIZE="0.0" ORDER="30593" O_E="0.0" SE="0.41917847549134185" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.1757105943152455" WEIGHT="10.001953983684235"/>
<DICH_DATA CI_END="1.360663708067324" CI_START="0.6147952102301713" EFFECT_SIZE="0.9146198830409357" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="38" LOG_CI_END="0.13375080134037534" LOG_CI_START="-0.21126952467702462" LOG_EFFECT_SIZE="-0.038759361668324645" ORDER="30594" O_E="0.0" SE="0.20266664738077883" STUDY_ID="STD-Risperidone-1998b" TOTAL_1="135" TOTAL_2="138" VAR="0.04107376996056495" WEIGHT="41.766401250549556"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30595" O_E="0.0" SE="0.0" STUDY_ID="STD-Risperidone-1999" TOTAL_1="15" TOTAL_2="14" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.3964281208304248" CI_START="0.02971524153919933" EFFECT_SIZE="0.2037037037037037" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.14501858591592467" LOG_CI_START="-1.5270207352454117" LOG_EFFECT_SIZE="-0.6910010746647435" ORDER="30596" O_E="0.0" SE="0.982164173978294" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.9646464646464646" WEIGHT="6.001172390210542"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.385951890323943" CI_START="0.683051419565939" DF="0.0" EFFECT_SIZE="0.972972972972973" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" I2="0.0" ID="CMP-001.12.02" LOG_CI_END="0.1417481551463005" LOG_CI_START="-0.16554660174571587" LOG_EFFECT_SIZE="-0.011899223299707707" NO="2" P_CHI2="1.0" P_Z="0.8793530134860807" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="41.1191441551463" Z="0.15178943726412075">
<NAME>medium term</NAME>
<DICH_DATA CI_END="1.385951890323943" CI_START="0.683051419565939" EFFECT_SIZE="0.972972972972973" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="37" LOG_CI_END="0.1417481551463005" LOG_CI_START="-0.16554660174571587" LOG_EFFECT_SIZE="-0.011899223299707707" ORDER="30597" O_E="0.0" SE="0.1805064613319495" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.03258258258258258" WEIGHT="41.1191441551463"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.4716978159358227" CI_END="2.126247761442739" CI_START="0.6627631910330779" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="RR" EFFECT_SIZE="1.1870967741935483" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="16" I2="19.0839597338573" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="0.32761386938672643" LOG_CI_START="-0.17864161970823655" LOG_EFFECT_SIZE="0.07448612483924495" METHOD="MH" NO="13" P_CHI2="0.2905880584607764" P_Q="0.0" P_Z="0.5641118355716108" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="119" WEIGHT="100.0" Z="0.5767448459427557">
<NAME>Acceptability of treatment: 2. Patient dissatisfaction</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="7.042103120709159" CI_START="0.7188903532401258" EFFECT_SIZE="2.25" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.8477023803517534" LOG_CI_START="-0.1433373441290284" LOG_EFFECT_SIZE="0.3521825181113625" ORDER="30598" O_E="0.0" SE="0.582141639885766" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.33888888888888885" WEIGHT="25.806451612903224"/>
<DICH_DATA CI_END="1.835018515395031" CI_START="0.27803756602576823" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.26364045065531494" LOG_CI_START="-0.5558965220117909" LOG_EFFECT_SIZE="-0.146128035678238" ORDER="30599" O_E="0.0" SE="0.48140007451809946" STUDY_ID="STD-Remoxipride-1994" TOTAL_1="18" TOTAL_2="18" VAR="0.23174603174603173" WEIGHT="45.16129032258064"/>
<DICH_DATA CI_END="2.594883396499179" CI_START="0.3684363559479702" EFFECT_SIZE="0.9777777777777777" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.41411784719613615" LOG_CI_START="-0.43363752177444864" LOG_EFFECT_SIZE="-0.009759837289156264" ORDER="30600" O_E="0.0" SE="0.49797570019007753" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="11" VAR="0.247979797979798" WEIGHT="29.032258064516128"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.3683629314570651" CI_START="0.2526373195905812" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="PETO_OR" EFFECT_SIZE="0.5879621954092143" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="0.13620130076463205" LOG_CI_START="-0.5975024950510878" LOG_EFFECT_SIZE="-0.23065059714322786" METHOD="PETO" NO="14" P_CHI2="1.0" P_Q="1.0" P_Z="0.21784187821757606" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="98" TOTAL_2="37" WEIGHT="100.0" Z="1.232287105481806">
<NAME>Cognitive functioning: 1. No improvement in memory (SKT) - short term</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.368362931457065" CI_START="0.2526373195905812" EFFECT_SIZE="0.5879621954092143" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="13" LOG_CI_END="0.13620130076463197" LOG_CI_START="-0.5975024950510878" LOG_EFFECT_SIZE="-0.23065059714322786" ORDER="30601" O_E="-2.859259259259261" SE="0.43098124155451745" STUDY_ID="STD-Remox_x002f_Risp_x002f_Zote-1996" TOTAL_1="98" TOTAL_2="37" VAR="5.383729910120182" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.010884442168313666" CI_END="1.061064091616535" CI_START="0.3569041944253555" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="26" I2="0.0" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="0.025741617449625893" LOG_CI_START="-0.44744834807941225" LOG_EFFECT_SIZE="-0.21085336531489315" METHOD="MH" NO="15" P_CHI2="0.9169086388143892" P_Q="0.0" P_Z="0.0806860560167915" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="86" TOTAL_2="86" WEIGHT="200.0" Z="1.7467192127551445">
<NAME>Cognitive functioning: 2. Problem with cognitive function - short term</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.4860901727243956" CI_START="0.27249939816475216" DF="0.0" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" I2="0.0" ID="CMP-001.15.01" LOG_CI_END="0.17204516227010241" LOG_CI_START="-0.5646344525580389" LOG_EFFECT_SIZE="-0.19629464514396822" NO="1" P_CHI2="1.0" P_Z="0.2962547544622366" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.00000000000001" Z="1.044498658836925">
<NAME>concentration difficulties</NAME>
<DICH_DATA CI_END="1.4860901727243956" CI_START="0.2724993981647522" EFFECT_SIZE="0.6363636363636364" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="11" LOG_CI_END="0.17204516227010241" LOG_CI_START="-0.5646344525580388" LOG_EFFECT_SIZE="-0.19629464514396822" ORDER="30602" O_E="0.0" SE="0.4327292523729555" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.18725460585925702" WEIGHT="100.00000000000001"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2205266832054942" CI_START="0.294954633072441" DF="0.0" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" I2="0.0" ID="CMP-001.15.02" LOG_CI_END="0.0865472784211566" LOG_CI_START="-0.5302447776538693" LOG_EFFECT_SIZE="-0.22184874961635637" NO="2" P_CHI2="1.0" P_Z="0.15856155270681202" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.4099259385092087">
<NAME>memory problems</NAME>
<DICH_DATA CI_END="1.2205266832054942" CI_START="0.294954633072441" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.0865472784211566" LOG_CI_START="-0.5302447776538693" LOG_EFFECT_SIZE="-0.22184874961635637" ORDER="30603" O_E="0.0" SE="0.3623067069083887" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.13126614987080104" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="5.119377370561143" CI_START="-19.119377370561143" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-7.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.16" NO="16" P_CHI2="1.0" P_Q="1.0" P_Z="0.2576131989953433" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="17" TOTAL_2="17" UNITS="" WEIGHT="100.0" Z="1.132050556087696">
<NAME>Cognitive functioning: 3. Intelligence endpoint score (KAI, high = good) - short term</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<CONT_DATA CI_END="5.119377370561143" CI_START="-19.119377370561143" EFFECT_SIZE="-7.0" ESTIMABLE="YES" MEAN_1="-114.0" MEAN_2="-107.0" ORDER="30604" SD_1="19.0" SD_2="17.0" SE="6.183469424008423" STUDY_ID="STD-Remoxipride-1994" TOTAL_1="17" TOTAL_2="17" WEIGHT="100.0"/>
</CONT_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.17" NO="17" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO">
<NAME>Cognitive functioning: 4. SKT (high = poor, data skewed) - short term</NAME>
<TR>
<TH>
<P>New atypical</P>
</TH>
<TH>
<P>Clozapine</P>
</TH>
<TH>
<P>Notes</P>
</TH>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="52" STUDY_ID="STD-Remoxipride-1994">
<TR>
<TD>
<P>Baseline: mean 7.7, SD 3.7.<BR/>Endpoint: mean 3.6, SD 4.8.</P>
</TD>
<TD>
<P>Baseline: mean 8.0, SD 3.9.<BR/>Endpoint: mean 3.6, SD 1.9.</P>
</TD>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-0.449308052902623" CI_START="-93.55069194709738" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-47.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.18" NO="18" P_CHI2="1.0" P_Q="1.0" P_Z="0.04782933953806504" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="1.9788815895168772">
<NAME>Social functioning: 1. SFS endpoint score (high = good) - short term</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.449308052902623" CI_START="-93.55069194709738" EFFECT_SIZE="-47.0" ESTIMABLE="YES" MEAN_1="-734.0" MEAN_2="-687.0" ORDER="30606" SD_1="54.0" SD_2="49.0" SE="23.7507894605632" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="2.7671198095342135" CI_START="-2.5671198095342107" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.19" NO="19" P_CHI2="1.0" P_Q="1.0" P_Z="0.9414192554087906" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="10" UNITS="" WEIGHT="100.0" Z="0.07348616202143433">
<NAME>Treatment satisfaction: 1. DAI-10 endpoint score (high = good) - short term</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<CONT_DATA CI_END="2.7671198095342135" CI_START="-2.5671198095342107" EFFECT_SIZE="0.10000000000000142" ESTIMABLE="YES" MEAN_1="-16.0" MEAN_2="-16.1" ORDER="30607" SD_1="3.1" SD_2="2.8" SE="1.3608004180546749" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" WEIGHT="100.0"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="11.805059208295848" CI_END="3.494933914830301" CI_START="1.2046374708010916" CI_STUDY="95" CI_TOTAL="95" DF="5.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0518597300444616" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="18" I2="57.64527808139822" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="0.5434389681515486" LOG_CI_START="0.08085636797373545" LOG_EFFECT_SIZE="0.31214766806264194" METHOD="MH" NO="20" P_CHI2="0.037558826534376255" P_Q="0.0" P_Z="0.008165679301057396" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="273" TOTAL_2="212" WEIGHT="200.0" Z="2.64514137378177">
<NAME>Adverse effects: 1. Extrapyramidal symptoms</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.3910327152018094" CI_START="0.14200303273879028" DF="0.0" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" I2="0.0" ID="CMP-001.20.01" LOG_CI_END="0.14333734412902846" LOG_CI_START="-0.8477023803517534" LOG_EFFECT_SIZE="-0.35218251811136253" NO="1" P_CHI2="1.0" P_Z="0.16361620031434898" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0" Z="1.3930118731507648">
<NAME>olanzapine</NAME>
<DICH_DATA CI_END="1.3910327152018094" CI_START="0.14200303273879028" EFFECT_SIZE="0.4444444444444444" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="9" LOG_CI_END="0.14333734412902846" LOG_CI_START="-0.8477023803517534" LOG_EFFECT_SIZE="-0.35218251811136253" ORDER="30608" O_E="0.0" SE="0.582141639885766" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.33888888888888885" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="4.574402772461307" CI_END="7.056466014167863" CI_START="1.7895145260293344" DF="4.0" EFFECT_SIZE="3.5535402677872825" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="9" I2="12.55689105295474" ID="CMP-001.20.02" LOG_CI_END="0.8485872541955517" LOG_CI_START="0.2527352280396747" LOG_EFFECT_SIZE="0.5506612411176133" NO="2" P_CHI2="0.33381631734680317" P_Z="2.9162097132365625E-4" STUDIES="5" TAU2="0.0" TOTAL_1="183" TOTAL_2="122" WEIGHT="100.0" Z="3.6226316363663966">
<NAME>all other newer atypicals</NAME>
<DICH_DATA CI_END="229.84078118884827" CI_START="0.8775526117485023" EFFECT_SIZE="14.202020202020202" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="0" LOG_CI_END="2.361427089077824" LOG_CI_START="-0.056726836905313854" LOG_EFFECT_SIZE="1.1523501260862552" ORDER="30609" O_E="0.0" SE="1.4204355861774796" STUDY_ID="STD-Remox_x002f_Risp_x002f_Zote-1996" TOTAL_1="98" TOTAL_2="37" VAR="2.01763725447936" WEIGHT="7.501041639451114"/>
<DICH_DATA CI_END="38.65426714707345" CI_START="0.6467591250631892" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.5871974438205523" LOG_CI_START="-0.18925743514851456" LOG_EFFECT_SIZE="0.6989700043360189" ORDER="30610" O_E="0.0" SE="1.043498389499902" STUDY_ID="STD-Remoxipride-1994" TOTAL_1="18" TOTAL_2="18" VAR="1.0888888888888888" WEIGHT="10.380229339442451"/>
<DICH_DATA CI_END="4.680805125661779" CI_START="0.21363846029770756" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" LOG_CI_END="0.6703205606720961" LOG_CI_START="-0.6703205606720961" LOG_EFFECT_SIZE="0.0" ORDER="30611" O_E="0.0" SE="0.7874992309581577" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.6201550387596898" WEIGHT="31.140688018327353"/>
<DICH_DATA CI_END="17.681283431552767" CI_START="1.2316853503357512" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="1.2475137859604954" LOG_CI_START="0.09049977595665581" LOG_EFFECT_SIZE="0.6690067809585756" ORDER="30612" O_E="0.0" SE="0.6796357567879738" STUDY_ID="STD-Risperidone-1999" TOTAL_1="15" TOTAL_2="14" VAR="0.46190476190476193" WEIGHT="21.47633656436369"/>
<DICH_DATA CI_END="6.372275863994501" CI_START="0.7749619932246131" EFFECT_SIZE="2.2222222222222223" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8042945687011667" LOG_CI_START="-0.110719596251854" LOG_EFFECT_SIZE="0.3467874862246563" ORDER="30613" O_E="0.0" SE="0.5374838498865699" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" VAR="0.28888888888888886" WEIGHT="29.501704438415388"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.9570085745955779" CI_START="0.31088609763267167" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" I2="0.0" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-0.01908417101849469" LOG_CI_START="-0.5073986985306682" LOG_EFFECT_SIZE="-0.26324143477458145" METHOD="MH" NO="21" P_CHI2="1.0" P_Q="0.0" P_Z="0.03458694671407663" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.00000000000001" Z="2.1131615068895">
<NAME>Adverse effects: 2. Fatigue</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical better</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine better</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9570085745955779" CI_START="0.31088609763267167" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="-0.01908417101849469" LOG_CI_START="-0.5073986985306682" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="30614" O_E="0.0" SE="0.28683837065654594" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.08227625088090204" WEIGHT="100.00000000000001"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="10.35067319986737" CI_START="0.3864482940154323" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" I2="0.0" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="1.0149685968924291" LOG_CI_START="-0.4129086055644666" LOG_EFFECT_SIZE="0.3010299956639812" METHOD="MH" NO="22" P_CHI2="1.0" P_Q="0.0" P_Z="0.40857001147857763" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="0.8264127317845636">
<NAME>Adverse effects: 3. Libido decrease</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="10.35067319986737" CI_START="0.3864482940154323" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0149685968924291" LOG_CI_START="-0.4129086055644666" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="30615" O_E="0.0" SE="0.8387421368293256" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.7034883720930232" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.7328701474637995" CI_END="0.9151527605079248" CI_START="0.19372210434153142" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" I2="73.2109620614737" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="-0.03850640592455778" LOG_CI_START="-0.7128208219972131" LOG_EFFECT_SIZE="-0.37566361396088543" METHOD="MH" NO="23" P_CHI2="0.053351899592197105" P_Q="0.0" P_Z="0.02897624056071261" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="2.183809617933961">
<NAME>Adverse effects: 4. Nausea/vomiting</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.7650398309944366" CI_START="0.01307121485034513" EFFECT_SIZE="0.1" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="10" LOG_CI_END="-0.11631595317216839" LOG_CI_START="-1.8836840468278313" LOG_EFFECT_SIZE="-1.0" ORDER="30616" O_E="0.0" SE="1.0381607668264958" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="1.077777777777778" WEIGHT="52.631578947368425"/>
<DICH_DATA CI_END="1.899134658796006" CI_START="0.3185336378350606" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.27855575962836465" LOG_CI_START="-0.49684469847850066" LOG_EFFECT_SIZE="-0.10914446942506803" ORDER="30617" O_E="0.0" SE="0.45547406738614354" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.20745662606127724" WEIGHT="47.36842105263158"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.754836057843061" CI_END="0.853945993595701" CI_START="0.14587277764947176" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.35294117647058826" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="17" I2="43.014619768576" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="-0.06856959467988863" LOG_CI_START="-0.8360257473093718" LOG_EFFECT_SIZE="-0.45229767099463025" METHOD="MH" NO="24" P_CHI2="0.18527004130023395" P_Q="0.0" P_Z="0.02087729409194686" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="2.3101962044437614">
<NAME>Adverse effects: 5. Orthostatic dizziness</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.9790034428614738" CI_START="0.01596010730496572" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="8" LOG_CI_END="-0.00921578091074276" LOG_CI_START="-1.7969641930731446" LOG_EFFECT_SIZE="-0.9030899869919435" ORDER="30618" O_E="0.0" SE="1.0501322668015576" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="1.1027777777777779" WEIGHT="47.05882352941177"/>
<DICH_DATA CI_END="1.5225762517088164" CI_START="0.20271035684567337" EFFECT_SIZE="0.5555555555555556" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.18257905162815233" LOG_CI_START="-0.6931240618347645" LOG_EFFECT_SIZE="-0.255272505103306" ORDER="30619" O_E="0.0" SE="0.5143923436484397" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.2645994832041344" WEIGHT="52.94117647058824"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.503435157811309" CI_END="0.5693424229726334" CI_START="0.10567236326925619" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.24528301886792453" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="26" I2="88.24004674062347" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="-0.24462645473316602" LOG_CI_START="-0.9760385798547385" LOG_EFFECT_SIZE="-0.6103325172939523" METHOD="MH" NO="25" P_CHI2="0.0035447785601867565" P_Q="0.0" P_Z="0.0010716249955151126" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="180" TOTAL_2="180" WEIGHT="200.0" Z="3.271014278826683">
<NAME>Adverse effects: 6. Salivation problems</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="164.75875354320448" CI_START="0.4916278999328527" DF="0.0" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-001.25.01" LOG_CI_END="2.216848497709265" LOG_CI_START="-0.3083634788306151" LOG_EFFECT_SIZE="0.9542425094393249" NO="1" P_CHI2="1.0" P_Z="0.1385302979986526" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0" Z="1.4812862986503919">
<NAME>too little (dry mouth)</NAME>
<DICH_DATA CI_END="164.75875354320448" CI_START="0.4916278999328527" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.216848497709265" LOG_CI_START="-0.3083634788306151" LOG_EFFECT_SIZE="0.9542425094393249" ORDER="30620" O_E="0.0" SE="1.483322015020407" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="2.2002442002442004" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.3145163439924629" CI_START="0.01881352074808363" DF="0.0" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="26" I2="0.0" ID="CMP-001.25.02" LOG_CI_END="-0.5023567813115343" LOG_CI_START="-1.7255299233021393" LOG_EFFECT_SIZE="-1.1139433523068367" NO="2" P_CHI2="1.0" P_Z="3.571488442210348E-4" STUDIES="1" TAU2="0.0" TOTAL_1="90" TOTAL_2="90" WEIGHT="100.0" Z="3.569877029487593">
<NAME>too much (hypersalivation)</NAME>
<DICH_DATA CI_END="0.3145163439924629" CI_START="0.01881352074808363" EFFECT_SIZE="0.07692307692307693" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="26" LOG_CI_END="-0.5023567813115343" LOG_CI_START="-1.7255299233021393" LOG_EFFECT_SIZE="-1.1139433523068367" ORDER="30621" O_E="0.0" SE="0.7184979584099849" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.5162393162393163" WEIGHT="100.0"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" NO="26" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="10" WEIGHT="0.0" Z="0.0">
<NAME>Adverse effects: 7. Seizures</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="30622" O_E="0.0" SE="0.0" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.560734777614302" CI_END="1.0190458396160935" CI_START="0.49894939902436813" CI_STUDY="95" CI_TOTAL="95" DF="4.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7130584192439863" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="55" I2="0.0" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="0.008193720262126204" LOG_CI_START="-0.3019434961377177" LOG_EFFECT_SIZE="-0.14687488793779577" METHOD="MH" NO="27" P_CHI2="0.46870383294422946" P_Q="0.0" P_Z="0.06339644870952545" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="SUB" TOTAL_1="228" TOTAL_2="229" WEIGHT="300.0" Z="1.8564008146658597">
<NAME>Adverse effects: 8. Sleep problems</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.1299225153393392" CI_END="1.0930745723442041" CI_START="0.36438614953205417" DF="1.0" EFFECT_SIZE="0.6311111111111112" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" I2="0.0" ID="CMP-001.27.01" LOG_CI_END="0.038649791641217186" LOG_CI_START="-0.4384381390978291" LOG_EFFECT_SIZE="-0.19989417372830595" NO="1" P_CHI2="0.7185124734049522" P_Z="0.10050646424687534" STUDIES="2" TAU2="0.0" TOTAL_1="52" TOTAL_2="53" WEIGHT="100.00000000000001" Z="1.6424032384133733">
<NAME>drowsiness/sedation</NAME>
<DICH_DATA CI_END="1.1331511242283545" CI_START="0.372854062416177" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="20" LOG_CI_END="0.05428783399550992" LOG_CI_START="-0.4284611207097987" LOG_EFFECT_SIZE="-0.1870866433571444" ORDER="30623" O_E="0.0" SE="0.28356912563976383" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.08041144901610017" WEIGHT="93.33333333333334"/>
<DICH_DATA CI_END="8.009362066759007" CI_START="0.016785911702309583" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9035979265811878" LOG_CI_START="-1.7750550657040625" LOG_EFFECT_SIZE="-0.43572856956143746" ORDER="30624" O_E="0.0" SE="1.573454027214515" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" VAR="2.4757575757575756" WEIGHT="6.666666666666667"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="7.485869783900746" CI_START="0.5343400453748842" DF="0.0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" I2="0.0" ID="CMP-001.27.02" LOG_CI_END="0.8742422683267309" LOG_CI_START="-0.27218227699876857" LOG_EFFECT_SIZE="0.3010299956639812" NO="2" P_CHI2="1.0" P_Z="0.30333828089764814" STUDIES="1" TAU2="0.0" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.0293009726167948">
<NAME>insomnia</NAME>
<DICH_DATA CI_END="7.485869783900746" CI_START="0.5343400453748842" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.8742422683267309" LOG_CI_START="-0.27218227699876857" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="30625" O_E="0.0" SE="0.6734154528172214" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.4534883720930233" WEIGHT="100.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8061552665756835" CI_END="1.0731089339020152" CI_START="0.38787589720010945" DF="1.0" EFFECT_SIZE="0.6451612903225806" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" I2="0.0" ID="CMP-001.27.03" LOG_CI_END="0.030643810494572057" LOG_CI_START="-0.4113072068351551" LOG_EFFECT_SIZE="-0.1903316981702915" NO="3" P_CHI2="0.36925944912118924" P_Z="0.09137942610031391" STUDIES="2" TAU2="0.0" TOTAL_1="133" TOTAL_2="133" WEIGHT="100.0" Z="1.6881656966604623">
<NAME>too much sleep (hypersomnia)</NAME>
<DICH_DATA CI_END="1.0342562750946585" CI_START="0.2876662857373476" EFFECT_SIZE="0.5454545454545454" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="22" LOG_CI_END="0.014628164550113218" LOG_CI_START="-0.541111034099276" LOG_EFFECT_SIZE="-0.26324143477458145" ORDER="30626" O_E="0.0" SE="0.32644395624005135" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="0.10656565656565656" WEIGHT="70.96774193548387"/>
<DICH_DATA CI_END="2.0868265782183926" CI_START="0.37862439794335156" EFFECT_SIZE="0.8888888888888888" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.3194863593423063" LOG_CI_START="-0.42179140423706896" LOG_EFFECT_SIZE="-0.05115252244738131" ORDER="30627" O_E="0.0" SE="0.4354302277106338" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.1895994832041344" WEIGHT="29.032258064516128"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="1.2183562226463915" CI_START="0.32061641147243736" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="0.0857742857607916" LOG_CI_START="-0.4940142510726412" LOG_EFFECT_SIZE="-0.2041199826559248" METHOD="MH" NO="28" P_CHI2="1.0" P_Q="0.0" P_Z="0.16757206893463933" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="43" TOTAL_2="43" WEIGHT="100.0" Z="1.3800473417965777">
<NAME>Adverse effects: 9. Weight gain</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2183562226463915" CI_START="0.32061641147243736" EFFECT_SIZE="0.625" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="16" LOG_CI_END="0.0857742857607916" LOG_CI_START="-0.4940142510726412" LOG_EFFECT_SIZE="-0.2041199826559248" ORDER="30628" O_E="0.0" SE="0.34057065653550256" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="0.11598837209302325" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.9209148956177975" CI_END="2.177690395398176" CI_START="0.2687211089487941" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7649780245200092" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="23.4872452000184" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="0.3379961356916467" LOG_CI_START="-0.5706982169315445" LOG_EFFECT_SIZE="-0.11635104061994891" METHOD="MH" NO="29" P_CHI2="0.2701315600594697" P_Q="0.0" P_Z="0.6157270270460735" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="277" TOTAL_2="281" WEIGHT="99.99999999999999" Z="0.5019154097756781">
<NAME>Adverse effects: 10. White blood cell problems</NAME>
<GROUP_LABEL_1>New atypical</GROUP_LABEL_1>
<GROUP_LABEL_2>Clozapine</GROUP_LABEL_2>
<GRAPH_LABEL_1>New atypical best</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Clozapine best</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.6780329195458952" CI_START="0.023837434614110364" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.22480047653850477" LOG_CI_START="-1.6227404852105425" LOG_EFFECT_SIZE="-0.6989700043360187" ORDER="30629" O_E="0.0" SE="1.0852547064066471" STUDY_ID="STD-Olanzapine-1998" TOTAL_1="90" TOTAL_2="90" VAR="1.1777777777777778" WEIGHT="63.150589868147115"/>
<DICH_DATA CI_END="71.65227627955493" CI_START="0.12560661666750186" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8552299918017103" LOG_CI_START="-0.9009874823623858" LOG_EFFECT_SIZE="0.47712125471966244" ORDER="30630" O_E="0.0" SE="1.6190157878205267" STUDY_ID="STD-Risperidone-1998a" TOTAL_1="43" TOTAL_2="43" VAR="2.6212121212121207" WEIGHT="6.315058986814711"/>
<DICH_DATA CI_END="29.116114803736973" CI_START="0.32299791740199524" EFFECT_SIZE="3.066666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.464133423118012" LOG_CI_START="-0.4908002778662263" LOG_EFFECT_SIZE="0.48666657262589286" ORDER="30631" O_E="0.0" SE="1.1483377330360314" STUDY_ID="STD-Risperidone-1998b" TOTAL_1="135" TOTAL_2="138" VAR="1.3186795491143317" WEIGHT="12.491325468424705"/>
<DICH_DATA CI_END="8.009362066759007" CI_START="0.016785911702309583" EFFECT_SIZE="0.36666666666666664" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9035979265811878" LOG_CI_START="-1.7750550657040625" LOG_EFFECT_SIZE="-0.43572856956143746" ORDER="30632" O_E="0.0" SE="1.573454027214515" STUDY_ID="STD-Risperidone-2000" TOTAL_1="9" TOTAL_2="10" VAR="2.4757575757575756" WEIGHT="18.04302567661346"/>
</DICH_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.30" NO="30" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO">
<NAME>Adverse effects: 11. Extrapyramidal symptoms (data skewed) - short term</NAME>
<TR>
<TH>
<P>New atypical</P>
</TH>
<TH>
<P>Clozapine</P>
</TH>
<TH>
<P>Notes</P>
</TH>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="80" STUDY_ID="STD-Remox_x002f_Risp_x002f_Zote-1996">
<TR>
<TD>
<P>Baseline: mean 0.8, SD 1.9. <BR/>Endpoint: mean 1.7, sd 3.4.</P>
</TD>
<TD>
<P>Baseline: mean 1.0, SD 1.2.<BR/>Endpoint: mean 0.5, SD 1.0.</P>
</TD>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="81" STUDY_ID="STD-Remoxipride-1994">
<TR>
<TD>
<P>Baseline: mean 1.1, SD 2.1.<BR/>Endpoint: mean 2.9, SD 3.5.</P>
</TD>
<TD>
<P>Baseline: mean 1.8, SD 1.9.<BR/>Endpoint: mean 0.3, SD 1.1.<BR/>
</P>
</TD>
<TD/>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="82" STUDY_ID="STD-Risperidone-1999">
<TR>
<TD>
<P>Baseline: mean 12.07, SD 2.05.<BR/>Endpoint: mean 12.33, SD 1.63.</P>
</TD>
<TD>
<P>Baseline: mean 12.29, SD 1.73.<BR/>Endpoint: mean 11.36, SD 1.08.</P>
</TD>
<TD>
<P>SAS values usually not as high as here. If mean values valid, SDs equivocally low.<BR/>
</P>
</TD>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
<OTHER_OUTCOME COLS="5" ID="CMP-001.31" NO="31" ROWS_PER_STUDY="1" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO">
<NAME>Adverse effects: 12. Weight change at endpoint</NAME>
<TR>
<TH>
<P>New atypical</P>
</TH>
<TH>
<P>Clozapine</P>
</TH>
<TH>
<P>Notes</P>
</TH>
<TH/>
<TH/>
</TR>
<OTHER_DATA ORDER="83" STUDY_ID="STD-Olanzapine-1998">
<TR>
<TD>
<P>1. Olanzapine: mean +1.8 kg. <BR/>
</P>
</TD>
<TD>
<P>2. Clozapine:<BR/>mean +2.3 kg.</P>
</TD>
<TD>
<P>Endpoint values and SDs not reported.</P>
</TD>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
<OTHER_DATA ORDER="84" STUDY_ID="STD-Risperidone-1998a">
<TR>
<TD>
<P>1. Risperidone: mean +1.1 kg.<BR/>
</P>
</TD>
<TD>
<P>2. Clozapine:<BR/>mean +2.7 kg.*<BR/>
</P>
</TD>
<TD>
<P>Endpoint values and SDs not reported.<BR/>*Statistically significant within clozapine group but not calculated between groups.</P>
</TD>
<TD/>
<TD/>
</TR>
</OTHER_DATA>
</OTHER_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK>
<FEEDBACK_ITEM ID="FBK-01" NO="1">
<TITLE>Taylor 1998</TITLE>
<DATE_SUBMITTED>
<DATE DAY="" MONTH="" YEAR=""/>
</DATE_SUBMITTED>
<FEEDBACK_SUMMARY>
<P>A. Category: Objectives<BR/>The commentator asserts that the objective of the review is misleading, because no evidence exists that clozapine is more effective than newer atypical antipsychotic drugs. This lack of evidence may lead the reader to assume there is no difference. The question that should be answered is whether any atypical is efficacious in treatment resistant patients.<BR/>B. Category: Discussion<BR/>The lack of difference in the efficacy between clozapine and atypical is a type II error.</P>
</FEEDBACK_SUMMARY>
<FEEDBACK_REPLY>
<P>A. Category: Objectives<BR/>The stated objective of our review is to evaluate the effectiveness of clozapine for schizophrenia in comparison with newer atypical drugs. We would be interested in knowing whether newer atypical drugs are more effective, less effective or 'equivalent' to clozapine. The adverse effects of clozapine, such as weight gain, blood disorders and the need for (costly) weekly blood tests, make this a question of relevance to clinicians, decision makers and people with schizophrenia.</P>
<P>The commentator states that the question that should be asked is whether any atypical drug is efficacious in treatment resistant patients? The efficacy of clozapine, in this respect, is systematically reviewed by Wahlbeck et al. in another review on the Cochrane Library (Wahlbeck 1998). We recommend this review is read in conjunction with our own review - it demonstrates some benefit for clozapine in comparison with conventional drugs for this group of patients.</P>
<P>Clozapine has (rightly or wrongly) come to be seen as a 'gold standard' against which newer drugs have been tested - and it is the performance against this 'gold standard' that we review here.</P>
<P>B. Category: Discussion<BR/>The commentator's specific concern about the lack of statistical power is one that we have been at pains to draw attention to in the body of the review. In underpowered primary research, failure to detect a difference should not imply equivalence (Altman 1995). This misinterpretation (often made by the authors of the primary studies) is exacerbated by the frequent use of p values and significance tests, which are meaningless in establishing the equivalence of two compounds. Throughout, we have presented confidence limits around all point estimates and have drawn attention to the fact that these are unnecessarily wide and prevent us from knowing the equivalence, superiority or inferiority of clozapine when compared to new atypical antipsychotic drugs. </P>
<P>Should investigators and sponsors of comparative studies of the new atypical drugs wish to demonstrate the equivalence of their compounds to clozapine (and vice versa), they will need to address the problem of statistical power and conduct 'equivalence' studies. The sample size required to demonstrate (with any certainty) that one drug is as good as another (equivalence) is generally four times greater than that required for a 'comparative' trial (Jones 1996). The difference between 'comparative' and 'equivalence' trials is not one that is acknowledged by the authors of the primary studies.</P>
<P>Readers might conclude that more fundamental research is required to justify the adoption of both newer atypical drugs and clozapine in the management of newly diagnosed and treatment resistant schizophrenia.</P>
<P>References<BR/>Altman DG, Bland JM. Absence of evidence is not evidence of absence. BMJ 1995;311:485.<BR/>Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. BMJ 1996;313:36-9.<BR/>Wahlbeck K, Cheine M, Essali MA, Rezk E. Clozapine vs 'typical' neuroleptic medication for schizophrenia (Cochrane Review). In: The Cochrane Library, Issue 3, 1998. Oxford: Update Software.</P>
</FEEDBACK_REPLY>
<FEEDBACK_CONTRIBUTORS>
<P>Comment received from David Taylor, London, November 1998.<BR/>(David Taylor has received honoraria from Novartis, the manufacturer of clozapine, for lecturing.)<BR/>Reply from Arja Tuunainen and Stefan Leucht, Helsinki and Munich, June 1999.</P>
</FEEDBACK_CONTRIBUTORS>
</FEEDBACK_ITEM>
</FEEDBACK>
<APPENDICES/>
<EXTENSIONS/>
</COCHRANE_REVIEW>